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Abstract: Although the invention of right heart catheterisation in the 1950s enabled accurate clinical
diagnosis of pulmonary arterial hypertension (PAH), it was not until 2000 when the landmark
discovery of the causative role of bone morphogenetic protein receptor type II (BMPR2) mutations
shed new light on the pathogenesis of PAH. Since then several genes have been discovered, which now
account for around 25% of cases with the clinical diagnosis of idiopathic PAH. Despite the ongoing
efforts, in the majority of patients the cause of the disease remains elusive, a phenomenon often
referred to as “missing heritability”. In this review, we discuss research approaches to uncover
the genetic architecture of PAH starting with forward phenotyping, which in a research setting
should focus on stable intermediate phenotypes, forward and reverse genetics, and finally reverse
phenotyping. We then discuss potential sources of “missing heritability” and how functional genomics
and multi-omics methods are employed to tackle this problem.
Keywords: forward phenotyping; forward genetics; reverse genetics; reverse phenotyping;
pulmonary arterial hypertension; intermediate phenotypes; whole-genome sequencing; epigenetic
inheritance; genetic heterogeneity; phenotypic heterogeneity
1. Introduction
Rare diseases, such as pulmonary arterial hypertension (PAH), are enriched with underlying
genetic causes and are defined as life-threatening or chronically debilitating disorders with a prevalence
of less than 1 in 2000 [1]. Although individually characterised by low prevalence, in total, rare diseases
pose a significant burden to health care systems and a diagnostic challenge. Over 6000 rare diseases
have been reported to date (ORPHANET [2]) and new genotype-phenotype associations are discovered
every month [3]. Despite the several-fold increase in genetic diagnoses in the area of rare diseases [4],
the cause of the disease remains elusive in a significant proportion of cases.
Since the 2008 World Symposium on Pulmonary Hypertension (WSPH), the term “heritable PAH”
(HPAH) has been used to describe both familial PAH and sporadic PAH with an identified underlying
pathogenic variant [5] (Table 1). Family history is a vital disease component directly linked to the
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proportion of variation attributable to genetic factors, known as heritability [6,7]. Familial studies have
been used historically as a tool for gene mapping, with the classical example of twin studies commonly
used to disentangle the relative contribution of genes and environment to complex human traits [2].
In statistical terms, heritability is defined as a proportion of the phenotypic variance that can be
attributed to the variance of genotypic values:
H2 (broad sense) = Var (G) ÷ Var (p) (1)
H2 estimates are specific to the population, disease and circumstances on which they are
estimated [8]. In theory, total genotypic variance (Var(G)) can be divided into multiple components:
Var(A)total additive variance (breeding values); Var(D) —dominance variance (interactions between
alleles at the same locus); Var(I) —epistatic variance (interactions between alleles at different loci);
Var(G× E)—variation arising from interactions between genes and the environment.
Var (G) = Var (A) + Var (D) + Var (I) + Var (G × E) (2)
In practice, total genotypic variation is difficult to measure, although estimates can be made,
and the components of genotypic variation are nearly unattainable. Hence genetic studies usually
refer to heritability in its narrow sense, which is the proportion of the phenotypic variance that can be
attributed to favourable or unfavourable alleles.
h2 (narrow sense) = Var (A) ÷ Var (p) (3)
Recently, genome-wide association studies (GWAS) have enabled the estimation of additive
heritability attributed to common genetic variation (single nucleotide polymorphisms—SNPs), albeit
with a typically small effect size [9]. This has led to the issue of “missing heritability” [10], whereby
SNP-based estimates were not sufficient to explain prior heritability predictions arising from twin or
familial recurrence studies. To that effect, several hypotheses have been proposed (Figures 1 and 2)
including the complex interplay between genes and environment and the often overlooked potential
contribution of structural variation [11].
To date, about 75% of patients with a clinical diagnosis of idiopathic pulmonary arterial
hypertension (IPAH) have no defined genetic cause of the disease. This review outlines the role of
forward and reverse genomic and phenomic approaches as well as other omic technologies in the
search for missing heritability of PAH (Figure 1). Understanding the genetic architecture of PAH and its
dynamic interplay with the environment is a prerequisite to predict personalized patient risk, decipher
interaction pathways underlying the disease and develop strategies for therapy and prevention.
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genomiC varIation and Phenotype in Humans using Ensembl Resources (DECIPHER), ClinVar 
databases. Forward genetics—‘genotype to phenotype’ approach; reverse genetics—analysis of the 
impact of induced variation within a specific gene on gene function; reverse phenotyping—clinical 
assessment directed by genetic results. Abbreviations: TS—targeted sequencing; WES—whole-exome 
sequencing; WGS—whole-genome sequencing; siRNA—small interfering RNA; EHR—Electronic 
Healthcare Records. 
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genetics (2) and reverse genetics (3) and phenotyping (4). Public databases include, but are not limited
to, Online Mendelian Inheritance in Man (OMIM), Human Phenotype Ontology (HPO), DatabasE
of genomiC varIation and Phenotype in Humans using Ensembl Resources (DECIPHER), ClinVar
databases. Forward genetics—‘genotype to phenotype’ approach; reverse genetics—analysis of the
impact of induced variation within a specific gene on gene function; reverse phenotyping—clinical
assessment directed by genetic results. Abbreviations: TS—targeted sequencing; WES whole-exome
sequencing; WGS—whole-genome sequencing; siRNA—small interfering RNA; EHR—Electronic
Healthcare Records.
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Table 1. Definitions and changes to the classification of Group 1 PAH. Abbreviations:
WSPH—World Symposium on Pulmonary Hypertension; ERS/ESC—European Respiratory Society
and European Society of Cardiology; mPAP—mean pulmonary artery pressure; (R)—resting;
(E)—exercise; PAWP—pulmonary artery wedge pressure; PVR—pulmonary vascular resistance;
LV—left ventricle; PPH—primary pulmonary hypertension; BMPR2—Bone morphogenetic
protein receptor, type II; ACVRL1—Activin A receptor like type 1; SMAD9—SMAD Family
Member 9; CAV1—Caveolin 1; KCNK3—Potassium two pore domain channel subfamily
K member 3; PVOD/PCH—pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis;
PAH—pulmonary arterial hypertension; PH—pulmonary hypertension; PPHN—persistent pulmonary
















Introduction of the terms primary
(PPH) and secondary (related to
other conditions) pulmonary




mPAP(R) > 25 mmHg;
mPAP(E) > 30 mmHg;
PAWP < 15 mmHg;
PVR > 3 WU
Abandonment of the term primary
pulmonary hypertension, the
introduction of terms idiopathic and
familial PAH as well as associated
PAH, BMPR2 and ACVRL1




mPAP(R) ≥ 25 mmHg;
PAWP ≤ 15 mmHg
Exercise-induced PH removed
from the definition as
although (R) mPAP has been
shown to be stable across age
groups, (E) mPAP increases
with age hence based on the
available data it was not
possible to define a cutoff
Introduction of the terms idiopathic
(no family history, no precipitating
risk factor) and hereditary
(encompassing familial cases with
or without identified germline
mutations and PAH). Inclusion of
PH associated with Schistosomiasis
and PH associated with chronic




mPAP(R) ≥ 25 mmHg;
PAWP ≤ 15 mmHg; CO
normal or reduced




mPAP(R) ≥ 25 mmHg;
PAWP ≤ 15 mmHg;
PVR > 3 WU
Introduction of PVR to the
definition, a recommendation
to report PVR in WU; fluid
challenge may be helpful to
unmask occult LV diastolic
dysfunction
SMAD9, CAV1 and KCNK3 included




mPAP(R) ≥ 25 mmHg;
PAWP ≤ 15 mmHg
The clinical significance of a
mPAP between 21 and 24
mmHg is unclear
Group 1′ PVOD/PCH has been
expanded and includes idiopathic,
heritable, drug-, toxin- and
radiation-induced and associated
forms; PPHN includes a
heterogeneous
group of conditions that may differ
from classical PAH. As a
consequence, PPHN has been
sub-categorised as group I′′.
6th WSPH, Nice,
2018 [18]
mPAP(R) ≥ 20 mmHg;
PAWP ≤ 15 mmHg;
PVR ≥ 3 WU
PVR ≥ 3 WU should be used
as a diagnostic criterion for all
forms of PH
PAH long-term responses to calcium
channel blockers established as a
subtype of Group 1; PAH with overt
features of venous/capillaries
(PVOD/PCH) involvement
established as a subtype of Group 1
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2. Genetic and Phenotypic Heterogeneity
Discoveries in the field of rare diseases have been hampered by genetic and phenotypic
heterogeneity of these entities. Genetic heterogeneity is a situation in which sequence variation
in two or more genes results in the same or very similar phenotype. The degree of genetic heterogeneity
varies between different diseases (Figure 3A). For instance, sickle cell anaemia has only been associated
with mutations in one gene [19], Haemoglobin subunit β (HBB) and tuberous sclerosis [20] in two
genes, retinitis pigmentosa [21] with over 60 and intellectual disability with over 800 [22]. PAH also
shows high genetic heterogeneity (Figure 3B), with so far around ~20 risk genes reported [23] and
more expected to be found.
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PAH [25]; Wang et al., 2019—IPAH [26]). ‘?’ denotes uncertainty around number of genes involved in
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Genotypic heterogeneity is further complicated by phenotypic heterogeneity. Pulmonary hypertension
(PH) is a highly heterogeneous condition, defined as an elevation of mean pulmonary artery pressure
(mPAP) equal to or greater than 25 mmHg measured by right heart catheterisation (RHC) in the supine
position at rest [17]. This somewhat arbitrary threshold for defining PH was proposed at the 1st WSPH
in Geneva in 1973 and has now been challenged by a new body of evidence showing that normal mPAP
is 14 ± 3.3 mmHg, which suggests an upper limit of normal at 20 mmHg (14 mmHg + 2SD). This new
threshold has been endorsed by the 6th WSPH along with the inclusion of pulmonary vascular resistance
(PVR) and pulmonary artery wedge pressure (PAWP) cut-offs into the new haemodynamic definition.
This new definition categorises PH into three groups based on haemodynamic criteria: pre-capillary PH,
isolated post-capillary PH (IpcPH) and combined pre- and post-capillary PH (CpcPH) [18] (Table 1).
Haemodynamic definitions of PH encompass multiple cardiopulmonary entities that have been
classified into five groups: PAH, PH secondary to left heart disease, PH due to lung disease and/or
hypoxia, chronic thromboembolic pulmonary hypertension (CTEPH) or other pulmonary artery
obstructions, and PH with unclear and/or multifactorial mechanisms.
The clinical classification aims to categorise patients into groups according to pathophysiological
mechanisms, haemodynamics and therapeutic management. Despite this, there is persistent
heterogeneity within groups and subgroups, and not all patients fit easily into a single category,
which can be a reflection of genetic pleiotropy (Figure 4).
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I/H/APAH—idiopathic/hereditary/associated pulmonary arterial hypertension;
PVOD/PCH—pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis; SPS—small
patella syndrome; BPD—bronchopulmonary dysplasia; HHT—hereditary hemorrhagic telangiectasia.
Based on the recent advances in mechanistic understanding of the disease, the 6th WSPH proposed
new changes to the classification of PH, including two previously recognised phenotypes as the
subgroups of Group 1, namely “PAH long-term responders to calcium channel blockers” (Group 1.5) and
“PAH with overt features of venous/capillaries (Pulmonary veno-occlusive disease(PVOD)/Pulmonary
capillary haemangiomatosis (PCH)) involvement” (Group 1.6) [18]. Other phenotypes previously
reported in the literature and summarised in An Official American Society Statement: Pulmonary
Hypertension Phenotypes [27] such as “severe” PH in respiratory disease, maladaptive right ventricular
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(RV) hypertrophy, PH in elderly individuals, PAH in children and PAH with metabolic syndrome [28]
are awaiting clinical validation and confirmation of utility both in clinical practice and research settings.
3. Forward Phenotyping for Genetic Studies
A precise definition of the phenotype of interest is a cornerstone of any genetic study (Figure 1,
process 1). As described above, clinical diagnosis relies on clustering patients based on observable and
measurable traits, signs and symptoms, which are the product of genetic, epigenetic and environmental
factors. As a consequence, clinical phenotypes can be dynamic and reactive, which is useful and
desirable in the clinical setting but unsuitable for genetic studies. A distinction must be made between
clinical and research diagnosis, particularly diagnosis for genetic analysis. The former is usually
spread over time and acquired in several stages: history taking, physical examination, differential
diagnosis and confirmation, the latter usually needs to be ascertained during a single encounter.
To make this feasible and reliable, standardised checklist and operating procedures need to be in
place, diagnostic criteria should follow simple inclusion/exclusion rules and phenotypes need to be
described using controlled vocabulary to avoid ambiguity. Additionally, the data must be in a format
amenable to computational analysis. Finally, the validity of phenotypes is confirmed in test cohorts,
through functional studies and ultimately via reverse phenotyping (see below). The accuracy and
precision of phenotype measurements are of paramount importance. In genetic studies, the diagnosis
misclassification or admixture of phenocopies can significantly affect power to detect an association [29].
Equally, categorising biologically continuous phenotypes (i.e., age, mPAP, diffusing capacity of the
lungs for carbon monoxide (DLCO)) is prone to errors due to flaws in quantification methods and
arbitrary thresholds.
Phenotype optimisation for genetic studies aims at finding homogenous groups of patients
that likely share the same genetic architecture. This can be approached through various strategies.
For example, an extreme phenotype strategy aims at identifying rare variants with large effect sizes
through recruitment of patients with traits at either end of the phenotypic spectrum. These phenotypes
can be based on family history, age of onset, outcome, severity scores, biomarker levels, disease
trajectory or response to treatment [30–32]. Such stratification was proven to increase the power
to detect novel disease risk genes [30,33,34] and to be cost-effective [35]. Other strategies include
covariate-based methods which jointly estimate the effect of multiple variables and data reduction
techniques. Alternatively, intermediate phenotypes can be used. Intermediate phenotypes are features
closer to underlying biology that are at least as heritable as the phenotype itself, stable over time, and
are associated with the disease of interest [36].
Although clinical phenotyping remains the most widely used method of patient stratification both
in clinical practice and research, it requires substantial domain knowledge and is time-consuming.
Computational phenotyping based on clinical and/or “omics” datasets using machine learning might
be an alternative due to unparalleled diagnostic precision, accuracy and speed. Two recent publications
exemplify the power of computational tools in identifying disease phenotypes. Based on blood
cytokine profiles, a prospective observational study of Group 1 PAH discovered and validated four
immune phenotypes; importantly, these phenotypes differed in clinical outcomes despite the fact
that demographics, PAH aetiologies, comorbidities, and treatments were similar across clusters [37].
Likewise, clinical data mining using the Comparative Prospective Registry of Newly Initiated Therapies
for Pulmonary Hypertension (COMPERA) again revealed four clusters with differing survival and
response to therapy [38]. A viable alternative approach for clinical data mining is utilising phenotype
ontologies, such as Human Phenotype Ontology (HPO), which allow standardised, highly granular
and precise phenotyping across different disease domains [39]. Use of ontologies to define phenotypes
has already proven useful in identifying novel candidate genes for rare disorders [40]. Ontology-based
analysis of phenotypes has been further facilitated by the implementation of methods for manipulation,
visualisation and computation of semantic similarity between ontological terms and sets of terms [41].
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4. Forward Genetics
4.1. Concepts
Forward genetics is a classic molecular genetics approach used to elucidate the genetic
underpinnings of a mutant phenotype of interest [42]. Forward genetics is typically considered a
‘phenotype to genotype’ approach as mutant phenotypes are first observed before their corresponding
genes are identified (Figure 1, process 2). In humans, forward genetics approaches most
commonly include family-based linkage studies and/or genome-wide association studies (GWAS) and,
more recently, rare variant association studies (RVAS).
4.2. Methodology
4.2.1. Study Design
The two main approaches for studying the underlying genetics of PAH are family-based studies and
case-control studies. The former is based on studying inheritance patterns of genetic polymorphisms,
the second involves comparing genotype frequencies between cases and controls. Family-based studies
are effective when parental samples along with phenotype information are available and the disease in
question has a high penetrance; they are particularly useful for studying dichotomous traits and are
robust to population stratification [43]. Case-control studies are a viable alternative if the above criteria
are not met, although they have their own challenges which need to be addressed. To name the most
important:
1. Selection of cases (recognition of selection bias, incident vs. prevalent cases recruitment)
2. Case definition (precise definition of the phenotype that can be ascertained in a research setting)
3. Selection of controls (healthy vs. disease controls, matched in respect to age, sex and ethnicity,
having a comparable evaluation of presence or absence of the phenotype in question)
Power calculations in genetic studies are an absolute necessity as ignoring this basic step can lead
to both underpowered (risking false rejection of null hypothesis and characterised by wide sampling
distributions for sample estimates) and overpowered (wasteful and often unethical) experiments.
Factors limiting power to detect new genotype-phenotype associations which need to be accounted for
are phenotypic variance, phenocopies, the effect size of risk alleles and minor allele frequency (MAF),
with the last two factors driving the difference of sample sizes between GWAS and RVAS.
4.2.2. Statistical Methods
Prior to the widespread use of GWAS, the most important tool in genetics were linkage studies in
families, these were particularly useful in single-gene disorders in which implicated genes have large
effect sizes. GWAS on the other hand compares the frequency of common SNPs between unrelated
cases and controls. The associated SNPs are then considered markers of relevant regions that influence
the risk of the phenotype. In fact, power calculations provided evidence that GWAS are better than
linkage studies at detecting variation with small effect sizes [44]. Multiple statistical methods can be
applied in GWAS, for example, Pearson X2 test, normal approximation to Fisher’s Exact Test, logistic
regression, categorical model tests, Cochran–Armitage Trend test, and allele tests. The best method
depends on the mode of inheritance and trait frequency. Importantly, the assumptions used in various
tests may differ; these assumptions directly impact the results, as tests that assume the same mode
of inheritance should yield the same results (i.e., Cochran–Armitage Trend Additive test, Logistic
Regression Additive test and Allele test). Due to a large number of comparisons, adjustment for
multiple testing is necessary; therefore, the p-value threshold is Bonferroni corrected (which encourages
high type II error). Additionally, genotype and phenotype misclassification errors impact on power in
GWAS. Epistatic scenarios and modelling gene–environment interactions require yet another set of
methods and are computationally challenging although feasible [45].
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GWAS is unsuitable for single-variant testing, due to the potentially low prevalence of mutation
carriers and small effect size, which would both require unfeasibly large sample sizes. Instead, gene
and region-based aggregation approaches have been developed which compare mutation frequencies
between cases and controls within the boundaries of the gene. These techniques are appropriate
when different variants exhibit an equal risk of disease and thus have the same phenotypic impact.
For instance, several variants may result in LoF (e.g., nonsense, frameshift, essential splice site),
and thus analysis would determine the association by counting the presence of LoF variants between
cases and controls. Prior to association testing, quality control and filtering methods are utilised,
namely sequencing quality scores, MAF filters [46] (usually MAF of 1:10,000 for autosomal dominant
disorders and MAF of 1:1000 for autosomal recessive disorders) and in silico predictions. Predictions
include deleteriousness scores for missense variants such as PolyPhen-2 [47], Sorting Intolerant From
Tolerant (SIFT) [47,48], and rare exome variant ensemble learner (REVEL) [49], conservation scores
such as Genomic Evolutionary Rate Profiling (GERP) [50], PhyloP [51] or PhastCons [52], or the
Combined Annotation Dependent Depletion (CADD) score [53], which combines several metrics in
one score. Analysis of the protein-coding region, consisting of ~20,000 genes, requires adjustment for
multiple-testing. This can be done using the Bonferroni correction, where α = (0.05/20,000) ≈ 2.5 × 10−6).
Where several models are applied, this adjustment must be made more stringent by dividing by the
number of models tested. Region-based collapsing approaches hinge on the notion that different
regions within genes may vary in their tolerance to missense variation. An alternative approach,
particularly useful in smaller studies, is collapsing variants that belong to the same gene set (i.e.,
genes that belong to the same pathway). Candidate gene testing is a powerful approach to avoid
overcorrection and, therefore, false-negative results. This proved useful when investigating members
of the transforming growth factor-β (TGF-β) pathway, such as SMAD9 [54], which did not reach
statistical significance in the exome-wide analysis [24]. More recently, the same approach revealed an
association between TET2 and PAH, which was further supported by experimental evidence [55] but
did not reach exome-wide significance [25].
Complex genetic models such as recessive inheritance pose additional challenges. In the recessive
mode of inheritance, the MAF threshold must be more lenient as heterozygotes are unaffected
(higher MAF in reference populations); also, variants in cis configuration (affecting the same allele)
might be wrongly counted (as a pose to trans variants, which are those present on opposing alleles).
Similarly, testing for digenic inheritance is particularly problematic due to the large number of possible
combinations requiring testing and adjusting for [56].
A number of statistical methods have been developed to test for rare variant associations. Burden
tests [57–59] aggregate the information found within a predefined genetic region into a summary dose
variable. In weighted burden tests [60], variants are weighted according to their frequency or functional
significance. Adaptive burden tests [61] aim to account for bidirectional effects by selecting appropriate
weights. Variance component (kernel) tests such as (Sequence) Kernel Association Test (SKAT) [62]
allow to test risk and protective variants simultaneously but are underpowered when most variants
are causal, and effects are unidirectional. Omnibus tests such as SKAT-O [63], which combines burden
tests with the variance-component test, might be particularly useful when there is little knowledge
of the underlying disease architecture. In addition to frequentist approaches, a Bayesian statistical
framework offers a robust alternative. Bayesian model comparison methods such as BeviMed [64]
allow for the testing of associations between rare Mendelian disease and a genomic locus by comparing
support for a model where disease risks depend on genotypes at rare variant sites in the locus and a
genotype-independent “null” model. The prior probability in such models can vary across variants
(reflective of external biological information, i.e., depending on MAF, conservation scores, gene
ontologies, expression in the tissue of interest) or be constant for all genes/variants reflecting the prior
belief of the overall proportion of variants that are associated with a given phenotype.
Last but not least, an essential step in rare variant discovery is to ascertain the pathogenicity of a
given variant and its causative role in the disease. Not all damaging variants are pathogenic and in
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silico approaches alone are not enough to predict if the variant is disease-causing [65]. Viability and
phenotyping inferred from knockout mice screens, as well as essentiality screens on human cell lines,
may further help predict variant impact [66]. To aid both research and clinical decision making, the
American College of Medical Genetics and the Association for Molecular Pathology (ACMG) issued
recommendations that combine and weigh the computational, functional, population and clinical
evidence to determine pathogenicity [67]. Other initiatives such as ClinGen and ClinVar aim to define
the clinical relevance of genes and variants reported in the literature for use in precision medicine
and research [68].
4.2.3. Molecular Genetic Techniques
Molecular genetics techniques used for genetic diagnosis, including the detection of specific
gene mutations and copy number variants, have been recently summarized [69]. Traditional methods
used to identify candidate genes involved in the pathogenesis of PAH include linkage analysis,
but more recently next-generation sequencing (NGS) has taken centre stage. The advent of NGS
technologies has opened a plethora of opportunities both for clinical diagnostics and research. Such
technologies that fall under the umbrella of NGS include targeted panel sequencing, whole-exome
sequencing (WES) and whole-genome sequencing (WGS). Nevertheless, the need for more conventional
methods such as Sanger sequencing and multiplex ligand-dependent probe amplification (MLPA)
remains. Disease-specific panels include a set of genes or regions of genes that are known to be
causative of a specific phenotype. This is particularly beneficial in the clinical context when assessing
highly heterogeneous traits, such as intellectual disability. Although these panels are not always
consistent across laboratories, efforts are being made to produce guidance around their design and
development [70]. Targeted panel testing has been introduced in PAH including known and candidate
disease genes [71].
WES includes < 2% of the genome i.e., the coding regions only. This method is clinically useful
given that 85% of all described disease-causing sequence variants are in this region [72]. For diseases
that are more genetically heterogeneous, WES has proven to be a fruitful method, especially when
incorporating segregation analysis, which increases the diagnostic yield from 23.6% in probands to 31%
in child–parent trios [73]. WES has been used for both the identification and discovery of candidate
genes in PAH and has been applied to family-based [74] and case-control studies [75]. Limitations
of WES include poor coverage of some exons such as GC rich regions and low confidence to identify
structural variation [76].
WGS is a high-throughput sequencing technology predominantly used in the research setting [77].
WGS is massively parallel, DNA fragments are aligned to form a contiguous sequence. The cost of this
technology is halving approximately every two years [78]; however, the $1000 genome often referred
to is still some way off unless sequencing is performed at scale [79]; as an example, WGS is currently
being introduced to the UK National Health Service in collaboration with Genomics England.
European Respiratory Society and European Society of Cardiology (ERS/ESC) guidelines published
in 2015 recommended sequential testing starting with bone morphogenetic protein receptor type-2
(BMPR2) sequencing and MLPA in patients with sporadic/familial PAH and EIF2AK4 sequencing in
sporadic/familial PVOD/PCH [17], and this approach has been successfully used in many clinical and
research settings across the world [80]. With the decreasing cost of WES/WGS, a common practice is
now that of virtual panel testing whereby a selected number of genes are chosen for bioinformatics
analysis based on the individual’s phenotype. This also allows for data reanalysis when a novel
disease-gene is identified and/or another condition is suspected (emerging phenotype over time).
In the UK, this is coordinated at a national level via the Genomics England PanelApp tool; virtual
disease gene panels applied to WGS data are continuously curated and include a PAH panel [81].
As more patients with PAH are being tested via NGS methods, a diagnostic benefit is starting to
emerge (Figure 3C).
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Despite the benefits of NGS technologies, there are some challenges that require attention
and systematic solutions, among these, storage and handling of big data remains a significant
consideration, also management of incidental findings as well as the reporting of variants of unknown
significance (VUS).
Along with the growing number of research projects using NGS to uncover the genetic basis of
various diseases, there has been an ongoing effort to aggregate and harmonise WES and WGS data from
large-scale disease and population projects and to make them publicly available as a reference variome.
This started in 2012 with a funder project called Exome Aggregation Consortium (ExAC) which
harvested WES data from over 60,000 individuals; this was followed by The Genome Aggregation
Database (gnomAD), of which three versions have been released so far, covering 71,702 genomes
from unrelated individuals aligned against GRCh38 (v3). Also, in 2012, came the announcement
of the 100,000 genomes project by the UK Government. The project sequenced the genomes of
100,000 NHS patients with particular focus on those with rare disease(s) and cancer. Another useful
resource is the Trans-Omics for Precision Medicine (TopMed) program, which aims to sequence
over 120,000 well-phenotyped individuals as well as collect other omics datasets. The assertion of
ethnic diversity is an important consideration, and several initiatives such as KoVariome [82], Genes
and Health [83] and BioBank Japan [84] are addressing this issue. Furthermore, new disease cohort
genomic databases are being established. Examples include: NIHR BioResource Rare Disease Study
(NBR) [77], Inflammatory Bowel Disease BioResource [85], Genetic Links to Anxiety and Depression
(GLAD) [86] and Eating Disorders Genetics Initiative (EDGI) [87]. The advantages of these datasets are
numerous; first, they provide allele frequencies for diverse populations, second, they help to address
the overestimation of disease penetrance arising from the historical focus on multiplex pedigrees [88],
and third, through acknowledging variable penetrance, they help to identify genetic and environmental
disease modifiers [89].
4.2.4. Reference Genome
The Human Genome Project was completed in 2003 [90,91] and since then, successive iterations
of the human reference genome have been published, updated, and refined by the Genome Reference
Consortium (GRC). Recent versions include GRCh37 (hg19) and GCRh38 (hg38) released in 2009
and 2013, respectively. These are both composite genomes, i.e., derived from the sequence of several
anonymous donors; the make-up of these two assemblies is largely similar, with approximately 93% of
the primary assembly composed of sequences from 11 genomic clone libraries.
To date, most large-scale PAH studies have aligned their data to the GRCh37 reference genome
(Table 2), with only a couple of recent studies aligning their data to GRCh38 [25,55]. Even though
GRCh38 was released seven years ago, the transition from GRCh37 to GRCh38 has been a long process
and recent analyses have sought to compare the two reference panels. Guo et al. [92] demonstrated
that GRCh38 provides a more accurate analysis of human sequencing data due to the improved
annotation of the exome and the additional reads aligned to GRCh38, findings which indicate better
structural and sequence representation. In addition, Pan et al. [93] noted that GRCh38 had better
genome coverage, with a 5% increase in the number of SNVs identified. In comparison to GRCh37,
GRCh38 altered 8000 nucleotides, corrected several misassembled regions, filled in gaps, and increased
the number of genes and protein-coding transcripts [92]; additionally, GRCh38 is the first human
reference genome to contain sequence-based representations for the centromeres [94]. Whilst GRCh37
is a single representation of multiple genomes, with only three regions containing alternative sequences
(UDP-glucuronosyltransferases 2B subfamily (UGT2B) on chromosome 4, the major histocompatibility
complex (MHC) region on chromosome 6, and the MAPT gene on chromosome 17) [95], GRCh38
includes 261 alternate loci across 178 genomic regions, providing a more robust representation of
human population variation [94]. The increased level of alternative sequence representation requires
new analysis methods to support their inclusion yet at present, most tools and pipelines do not make
use of these [95]. Despite the advantages, GRCh38 still contains gaps and errors at repetitive and
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structurally diverse regions [96]. Additionally, as it is a mosaic haploid representation of the human
genome [94], in which poor alignment can affect the detection of alleles in regions of high variation,
such as the MHC locus and KIR, it is unlikely to truly represent human diversity [96]. It does, however,
provide the starting point for a more inclusive population-based reference genome, or pan-genome [97]
and as such, will play an evolving role in the generation of individual diploid genome assemblies and
graph-based representations of genome-wide population variation [98–100], thereby providing unique
opportunities for data analysis.
Table 2. Landmark forward genetics studies in Group 1 PAH. Abbreviations: BMPR2—Bone
morphogenic protein receptor type 2; ENG—Endoglin; ACVRL1—Activin A Receptor Like Type
1; SMAD—SMAD Family Member; CAV1—Caveolin 1; KCNK3—Potassium Two Pore Domain Channel
Subfamily K Member 3; TBX4—T-Box Transcription Factor 4; EIF2AK4—Eukaryotic Translation
Initiation Factor 2 α Kinase 4; GDF2—Growth Differentiation Factor 2; SOX17—SRY-Box Transcription
Factor 17; ATP13A3—ATPase 13A3; AQP1—Aquaporin 1; ABCC8—ATP Binding Cassette Subfamily
C Member 8; BMP10—Bone Morphogenetic Protein 10; KLK1—Kallikrein 1; GCCX—γ-Glutamyl
Carboxylase; KDR—Kinase insert domain receptor; TET2—Tet Methylcytosine Dioxygenase 2;
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4.3.1. Rare Genetic Variation
Over the last two decades, forward genetics approaches have associated PAH with numerous
genes (Table 2); the level of evidence supporting the causal role of these genes, however, is variable
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and depends on multiple factors (Table 3). PAH is considered to be a monogenic condition transmitted
in autosomal dominant fashion with incomplete penetrance. Heterozygous germline mutations in
BMPR2, a member of the TGF-β superfamily, are the most common genetic cause of PAH [101,119],
accounting for over 80% of familial PAH, and approximately 25% of idiopathic PAH [24]. Additional
mutations within the TGF-β/BMP signalling pathway, such as activin A like type 1 (ACVRL1), endoglin
(ENG), SMAD family members (SMAD1, SMAD4, SMAD9), caveolin 1 (CAV1), growth differentiation
factor 2 (GDF2), loss of function variants in channelopathy genes, potassium two pore domain channel
subfamily K member 3 (KCNK3), ATP binding cassette subfamily C member 8 (ABCC8), ATPase
type 13A3 (ATP13A3), variants within developmental transcription factors, SRY-box transcription
factor 17 (SOX17) and T-box transcription factor 4 (TBX4), and newly reported risk genes, γ-glutamyl
carboxylase (GGCX), kallikrein 1 (KLK1) [25], kinase insert domain receptor (KDR) [30], fibulin 2 (FBLN2)
and platelet-derived growth factor D (PDGFD) [118], have all been identified as individually rare
causes of PAH. Infrequent cases of autosomal recessive transmission in KCNK3 [120] and GDF2 [121]
have been associated with early disease onset and severe phenotype. A subtype of PAH, PVOD/PCH
is linked to biallelic mutations in EIF2AK4 [109].
Table 3. Supporting evidence for the role of risk genes in PAH pathogenesis. Abbreviations: (+)
indicates that the paper provides information in favour of the role of the given gene in the pathogenesis
of PAH, (−) indicates that the paper does not provide support for the role of the given gene in the
pathogenesis of PAH.
Forward Genetics Reverse Genetics




Aberration Disease Model Rescue
MOI: Autosomal Dominant







ACVRL1 (+) [24] (+)[25,103,105,114] (+) [103]
ENG (−) [24,25] (+) [24,75,104] (+) [104] Animal: (−) [132]





SMAD1 (−) [24,25] (+) [54], (−) [24,25] (+) [54,136] Animal: (+) [136] Cellculture: (+) [54]
SMAD4 (−) [24,25] (+) [25,54], (−) [24] (+) [54], (−) [54] Cell culture: (+) [54]




KCNK3 (+) [24,25,107] (+) [107] (+) [107,145] Animal: (+) [146] Cellculture: (+) [107,145] (+) [107]
ATP13A3 (+) [24] (+) [147,148] Animal: (+) [147,148]
AQP1 (+) [24] (+) [149,150] (−)[149]
Animal: (+) [149,151]
Cell culture: (+) [150] (+) [149]
GDF2 (+) [24–26] (+) [114] (+) [115] (+) [26,115] Animal: (−) [152] Cellculture: (+) [26,115]
SOX17 (+) [24,75] (+) [112] (+) [153,154] Animal: (+) [153] Cellculture: (+) [154]
ABCC8 (+) [113] (+) [113] (+) [113] Cell culture: (+) [113] (+) [113]
BMP10 (+) [114,115]
GGCX (+) [25]
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Table 3. Cont.
Forward Genetics Reverse Genetics




Aberration Disease Model Rescue
KLK1 (+) [25]
KDR (+) [30] (+) [30,117] (+) [155] Animal: (+) [155]
FBLN2 (+) [118]
PDGFD (+) [118]
TET2 (+) [55] (+) [55] Animal: (+) [55] (+) [55]
BMPR1A (+) [25,75] (+) [156–159] Animal: (+)[156,157,159] (+) [156]
BMPR1B (+) [24,25,75] (+) [160] Cell culture: (+) [160]
TOPBP1 (+) [24]
THBS1 (+) [161] Cell culture: (+) [161] (+) [161]
KCNA5 (+) [162] (+) [163] Cell culture: (+) [163] (+) [163]
MOI: Autosomal Recessive
EIF2AK4 (+) [111] (+) [114] (+) [109,110] (+) [109] Animal: (+) [164]
Common Variation
enhancer near
SOX17 (+) [116] (+) [116] (+) [116]
locus within
HLA-DPA1/DPB1 (+) [116]
CBLN2 (+) [165](−) [116]
SIRT3 (+) [166] (+) [166] (+) [166] Animal: (+) [166,167]
UCP2 (+) [168] Animal: (+) [167,169]
EDN1 (+) [170] (+) [171]
AGTR1 (+) [34]
TOPBP1 (+) [172] (+) [172] Cell culture: (+) [172]
Endostatin (+) [173]
TRPC6 (+) [174] Cell culture: (+) [174]
Autosomal Dominant Mode of Inheritance
TGF-ß Pathway
In 2000, the International Primary Pulmonary Hypertension (PPH) Consortium demonstrated that
familial PAH (FPAH) is caused by mutations in BMPR2, located on chromosome 2, encoding a TGF-β
type II receptor [101]. They established a panel of eight kindreds, in which at least two members had
the typical manifestations of PAH. Sequence variants were detected in seven probands; these variants,
including two frameshift, two nonsense and three missense mutations, were distributed across the gene
and each of the amino acid substitutions occurred at a highly conserved and functionally important
site of the BMPR2 protein. They observed segregation of the mutations with the disease phenotype
in seven of the eight families studied. As control subjects, they screened 150 normal chromosomes
from the same population and 64 normal chromosomes from ethnically diverse subjects and observed
no BMPR2 mutations [101]. The predicted functional impact of these mutations, their segregation
with the phenotype, and the absence of these variants in healthy controls provided strong support
for the role of BMPR2 and the TGF-β signalling pathway in the pathobiology of PAH. The role of
BMPR2 mutations has been subsequently reported in IPAH. Thomson et al. [102] investigated BMPR2
gene mutations in 50 unrelated IPAH patients with no family history of the disease. In 13 patients
(26%), 11 novel heterozygous mutations in BMPR2 were identified, these included three missense,
three nonsense and five frameshift. They also sequenced both parents for five of the 13 probands;
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paternal transmission was observed for three families, whereas the remaining two mutations arose
spontaneously. BMPR2 mutations were not observed in 150 normal chromosomes [102]. Screening
of other disease subtypes revealed BMPR2 mutations among patients with PAH associated with
congenital heart disease (PAH-CHD) [175] and PVOD [176].
Large cohort studies have proved useful in defining the relative contribution of BMPR2 mutations
in various PAH subtypes. Gräf et al. [24] reported rare heterozygous BMPR2 mutations in 160 of
1048 PAH cases (15.3%); the frequency of BMPR2 mutations in FPAH, IPAH and anorexigen-exposed
PAH were 75.9%, 12.2% and 8.3%, respectively. Fourteen percent of BMPR2 mutations resulted in the
deletion of larger protein-coding regions, ranging from 5 kb to 3.8 Mb in size. Additionally, 52% of
the observed BMPR2 mutations were newly identified in their study [24], suggesting that nearly two
decades after the first BMPR2 mutation was identified, the use of WGS has allowed for closer study
of BMPR2, including large deletions around the BMPR2 locus, and the TGF-β pathway. Another
large-scale study in a more heterogeneous group of patients (Group 1 PAH) [25] reported BMPR2
mutations in 180 of 2572 cases (7%); the frequency of BMPR2 mutations in FPAH and IPAH patients
were 62.4% and 9.3%, respectively. Taken together, over 600 distinct mutations in BMPR2 have been
identified in PAH patients [24,25,177–179] of which around 70–80% are identified in FPAH and 10–20%
in IPAH [180].
Importantly, impaired BMPR2 signalling was shown to be a universal feature of PAH and pointed
towards other key members of the canonical BMPR2 signalling pathway as potential culprits for
the disease [181–183].
Mutations in ACVRL1 and ENG have been reported in PAH patients and in patients with PH in
association with hereditary hemorrhagic telangiectasia (HHT). HHT is a rare autosomal dominant
genetic disorder characterised by arteriovenous malformations and multiple telangiectasias [184]; it is
frequently linked to defects in ACVRL1 and ENG and as HHT and PAH may co-present in families,
suggests a common molecular aetiology [103–105]. Of note, PH secondary to high cardiac output
from arteriovenous fistulas is much more common in HHT, and such phenocopies, if unrecognised,
may introduce significant bias to the studies [185]. Conversely, I/HPAH associated with ACVRL1
and ENG can occur without clinical features of HHT [105,185,186], as the latter shows age-related
penetrance. In a large case-control study, which employed deep phenotyping prior to association
analysis, ACVRL1 was associated with HPAH [30] but fell just below the cut-off for significance when
studied in unselected patients with Group 1 PAH [25].
Two studies using targeted sequencing of BMPR2 signalling intermediates provided further
evidence supporting the role of this pathway in the pathogenesis of PAH. Shintani et al. [106] screened
23 patients with IPAH for mutations in ENG, SMAD1, SMAD2, SMAD3, SMAD4, SMAD5, SMAD6 and
SMAD9 (SMAD8) and identified a nonsense mutation in SMAD9 in a child who was diagnosed at eight
years of age and his unaffected father. The results of immunoblotting and co-immunoprecipitation
assays indicated that the SMAD9 mutant disturbs the downstream signalling of TGF-β/BMP. In a
later study, SMAD1, SMAD4, SMAD5 and SMAD9 were screened by direct sequencing in a cohort of
324 PAH cases (188 IPAH and 136 anorexigen-induced PAH) [54]. Four gene defects in three genes
were observed. A novel missense variant in SMAD1 was observed in an IPAH patient, a predicted
splice-site mutation and a missense variant in SMAD4 were observed in two IPAH patients and a novel
missense variant in SMAD9 was observed in a patient of Japanese origin. These four variants were
absent in the 960 European and 284 French control samples and the SMAD9 variant was excluded from
the panel of 340 Japanese controls. A case-control study using WGS detected two cases harbouring
protein-truncating variants in SMAD1, of which one co-existed with a protein-truncating variant in
BMPR2, and eight SMAD9 variants, two of which co-occurred with protein-truncating variants in
BMPR2 and GDF2; statistical analysis did not reveal significant association with studied phenotypes [30].
In another large cohort study (n = 2572 cases, 72% European), deleterious variants were observed in
SMAD1 (two cases), SMAD4 (two cases) and SMAD9 (13 cases) but were not statistically significant [25].
Taken together, these findings demonstrate that variations within the SMAD family have a small
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effect size, suggesting that a second genetic or environmental hit is needed, or that they perturb other
non-investigated pathways.
Besides BMPR2 mutations, CAV1 mutations are a rare cause of PAH. Variants in CAV1 were
initially implicated in PAH pathogenesis by exome sequencing of a three-generation family with
autosomal dominant HPAH who were negative for established variants in the TGF-β family [74].
They identified a frameshift mutation in CAV1; all PAH patients and several unaffected family members
carried the CAV1 mutation, suggesting incomplete penetrance. Subsequent evaluation of an additional
62 unrelated HPAH and 198 IPAH patients identified an independent de novo CAV1 mutation in a
child with IPAH. Two separate studies have since identified CAV1 mutations in PAH patients; the first
identified a novel heterozygous frameshift mutation in an adult PAH patient with a paediatric-onset
daughter who died at nine years old [140], and the second identified deleterious variants in 10 patients
with I/F/APAH, with three related cases carrying the same likely gene damaging mutation [25]. WGS
in an I/HPAH cohort did not detect deleterious variants in CAV1 [24]. Whilst these findings highlight
the importance of caveolae in the homeostasis of the pulmonary vasculature, the link between CAV1
mutations and PAH requires further study.
Bone morphogenetic protein (BMP)-9 (encoded by GDF2) and BMP10 are ligands involved in
TGF-β signalling pathway. Wang et al. [121] identified a novel homozygous nonsense mutation in
the GDF2 gene in a five-year-old Hispanic child with severe PAH. Genetic testing revealed that both
parents were heterozygous for the same mutation, indicating that the child inherited the GDF2 mutant
allele from each parent. This study was the first to report a novel homozygous nonsense mutation
in GDF2 in an IPAH patient, suggestive of the causative role of GDF2 mutations in PAH. Further
evidence came from the NBR study which identified associations between rare heterozygous missense
(n = 7) and frameshift variants (n = 1) in adult-onset IPAH (88% European) [24]; additionally, Hodgson
et al. [115] identified two patients with large deletions encompassing the GDF2 locus and several
neighbouring genes.
The identification of GDF2 mutations has since been independently replicated in a Chinese
cohort [26]. Wang et al. [26] performed an exome-wide gene-based burden analysis on two independent
case-control studies. The discovery analysis, containing 251 IPAH patients, identified rare heterozygous
mutations in BMPR2 (49 cases), ACVRL1 (15 cases), TBX4 (10 cases), SMAD1 (two cases), BMPR1B
(one case), KCNK3 (one case) and SMAD9 (one case). In a gene-based burden analysis (cases: n = 251;
controls: n = 1884), only three genes (BMPR2, GDF2 and ACVRL1) had an exome-wide significant
enrichment of mutations in IPAH cases when compared to healthy controls. GDF2 mutations were
identified in 17 cases (6.8%) and ranked second to BMPR2 (56 cases, 22.3%). To validate the risk
effects of GDF2, they performed WES in an independent replication cohort of 80 IPAH cases and in a
second gene-based burden analysis (cases: n = 80; controls: n = 8624), BMPR2, GDF2 and ACVRL1
were again identified as the top three disease-associated genes. Within this analysis, five additional
GDF2 heterozygous mutations were identified. Among the 331 IPAH patients, they identified 22 cases
carrying 21 distinct rare heterozygous mutations in GDF2, only two of which had been reported
previously [24], accounting for 6.7% of IPAH cases. An independent cohort confirmed the genome-wide
association of GDF2 among 1832 PAH and 812 IPAH cases of European ancestry [25]; twenty-four
GDF2 variants were observed in 28 cases, only two of which had been reported previously, and 75% of
these occurred in IPAH cases.
Additionally, gene panel sequencing of 263 PAH patients (180 IPAH, 11 FPAH, 13 drug and
toxin-induced PAH and 59 sporadic PVOD) revealed two (1.2%) BMP9 mutations in adult PAH
cases [114]; due to the close similarity of BMP9 and BMP10 (a close paralogue of BMP9 that encodes
an activating ligand for ACVRL1), the BMP10 gene was also included in the capture design. Two
mutations were identified in BMP10, a truncating mutation and a predicted loss of function variant
were identified in two severely affected IPAH patients. Two rare missense variants in BMP10 were
identified in patients with IPAH in an independent cohort [115]. These results emphasise the role of
GDF2 in the pathobiology of PAH and suggest BMP10 might act as a predisposing risk factor.
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Channelopathies
Channelopathies are a group of diseases caused by dysfunction of ion channels localised in
cellular membranes and organelles. These diseases include, but are not limited to, cardiac, respiratory,
neurological and endocrine disorders. LoF variants in channelopathy genes have also been reported
in PAH.
The first channelopathy described in PAH was caused by a genetic defect in KCNK3 in patients
with familial and sporadic PAH [107]. KCNK3 belongs to a family of mammalian potassium channels
and encodes for a two-pore potassium channel which is expressed in pulmonary artery smooth
muscle cells (PASMCs); this channel plays a role in the regulation of resting membrane potential and
pulmonary vascular tone and vascular remodelling [120]. In studying a family in which multiple
members had PAH, Ma et al. [107] identified a novel heterozygous missense variant in KCNK3 as a
disease-causing candidate gene within the family. WES was used to study an additional 10 probands
with FPAH and two novel heterozygous KCNK3 variants were identified and segregated with the
disease. In addition, three novel KCNK3 variants were identified in 230 patients with IPAH. These five
variants were predicted to be damaging. In summary, KCNK3 mutations were identified in three of
93 unrelated patients (3.2%) with FPAH and in three of 230 patients (1.3%) with IPAH [107].
In another study using targeted sequencing, two KCNK3 mutations were observed in three patients
from two families. One of these mutations, a homozygous missense variant in KCNK3, was identified
in a patient belonging to a consanguineous Romani family; his affected mother and asymptomatic
father were carriers of the same KCNK3 mutation. This is the first report of a young patient with severe
PAH carrying a homozygous mutation in KCNK3 [120]. Of note, in the Ma et al. [107] study, as the
pedigree suggested an autosomal dominant mode of inheritance, homozygous variants were excluded
from the analysis. The two biggest case-control studies, reported by Gräf et al. [24] and Zhu et al. [25],
identified heterozygous KCNK3 mutations in only four (0.4%) and three (0.1%) cases, respectively, and
did not show statistically significant associations.
Conversely, Gräf et al. [24] detected statistically significant enrichment of rare deleterious variants
in two new channel genes: ATP13A3 and AQP1. Utilising a rigorous case-control comparison
using a tiered search for variants, they searched for high-impact protein-truncating variants (PTVs)
overrepresented in cases and identified a higher frequency of PTVs in ATP13A3 (six cases). ATP13A3
is a poorly characterised member of the P-type ATPase family of proteins that transport a variety of
cations across membranes [187]; ATP13A3 is thought to play a role in polyamine transport [188]. Within
PAH cases, Gräf et al. [24] identified three heterozygous frameshift variants, two stop gain, two splice
region variants and four heterozygous likely pathogenic missense variants in ATP13A3. These variants
were predicted to lead to loss of ATPase catalytic activity, and to destabilise the conformation of
the catalytic domain; six variants were predicted to cause protein truncation, suggesting that loss of
function of ATP13A3 contributes to PAH pathogenesis.
Within the same study, SKAT-O analyses revealed a significant association with rare variants in
AQP1 [24]; AQP1 ranked second in their combined rare PTV and missense variant case-control analysis.
Along with statistical evidence, familial segregation of AQP1 variants with the phenotype was shown
in three families [24]. AQP1 belongs to the aquaporins family, a family of water-specific membrane
channel proteins that facilitate water transport in response to osmotic gradients [189]. Zhu et al. [25]
identified seven cases with ATP13A3 rare deleterious variants. However, ATP13A3 and AQP1 failed to
reach genome-wide significance in their study and additionally, AQP1 was not among the expanded
list of genes with p≤ 0.001 for either the whole cohort or the IPAH subset.
Interestingly, a mutation in ATPase Na+/K+ transporting subunit α 2 (ATP1A2), previously
associated with familial hemiplegic migraine (FHM), was reported in a 24-year old male with IPAH
and history of FHM [190]. Genetic analysis of the proband and two siblings (one with FHM) revealed
a nucleotide substitution in the coding sequence of the ATP1A2 gene for both the proband and the
affected sibling [190]. A co-occurrence of PAH and FHM supports the hypothesis of a potential common
pathophysiological link; several studies have reported the presence and activity of the α2-subunit of the
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Na+/K+-ATPase in pulmonary vascular smooth muscle cells [191,192], and the decrease in expression
and/or activity of different types of K+ channels in PASMCs of IPAH patients [193,194], and Montani
et al. [190] suggested that mutations in ATP1A2 may contribute to pulmonary arterial remodelling
through the disturbance of intracellular Ca2+ and K+ concentrations.
Mutations in ABCC8 have recently been identified as a potential second potassium channelopathy
in PAH [113]. ABCC8 encodes SUR1 (sulfonylurea receptor 1), a regulatory subunit of the ATP-sensitive
potassium channel; ABCC8 is highly expressed in the human brain and endocrine pancreas and
moderately expressed in human lungs [195]. Mutations in ABCC8 have previously been related to
type II diabetes mellitus and congenital hyperinsulinism [196]. In exome-sequencing a cohort of
99 paediatric- and 134 adult-onset Group 1 PAH patients (182 IPAH and 52 HPAH), Bohnen et al. [113]
identified a de novo heterozygous predicted deleterious missense variant in ABCC8 in a child with IPAH.
All individuals within this cohort and the second cohort of 680 adult-onset PAH patients (NBR study)
were screened for rare or novel variants in ABCC8. Eleven heterozygous predicted damaging ABCC8
variants were identified, seven of these were observed in the original cohort, including one familial case.
In a study of 2572 PAH cases, Zhu et al. [25] identified rare deleterious variants in newly reported risk
genes and nearly two-thirds of these variants were in ABCC8 (26 variants in 29 IPAH/APAH patients).
In a more recent study, utilising a custom NGS targeted sequencing panel of 21 genes, Lago-Docampo
et al. [197] identified 11 rare variants in ABCC8 within a cohort of 624 paediatric and adult patients
from the Spanish PAH registry. To date, ABCC8 variants have been identified in patients with IPAH,
FPAH, PAH-CHD and APAH and account for ~0.5–1.7% of cases.
Transcription Factors
An emerging category of HPAH is the one that can be labelled as a disorder of transcriptional
regulation. Interestingly, variants within developmental transcription factors are enriched in
paediatric patients.
The first transcription factor implicated in the pathogenesis of PAH was TBX4. TBX4, expressed
in the atrium of the heart, limbs, and the mesenchyme of the lung and trachea, encodes a transcription
factor in the T-box gene family [198]. Deletions and LoF mutations in TBX4 cause a variety of
developmental lung disorders [199] and have been identified as a prominent risk factor in small
patella syndrome (SPS) [200], childhood-onset PAH [108] and more recently, persistent pulmonary
hypertension in neonates [201]. In a 2013 study incorporating array-comparative hybridisation and
direct sequencing, three TBX4 mutations and three novel TBX4 microdeletions were detected in six out
of 20 children with I/HPAH and interestingly, features of SPS were detected in all living TBX4 mutation
carriers [108].
Zhu et al. [140] performed exome sequencing on a cohort of 155 paediatric- and 257 adult-onset
PAH patients. Within 13 probands (12 paediatric- and one adult-onset), they identified 13 likely
pathogenic/predicted highly deleterious TBX4 variants; eight of these variants were inherited from
an unaffected parent, whereas one was de novo. This pattern is consistent with the incomplete
penetrance observed for BMPR2 mutation carriers [122]. Similar frequencies of rare, deleterious
BMPR2 mutations were observed in paediatric- and adult-onset I/FPAH patients; however, there was
significant enrichment of rare, predicted deleterious TBX4 mutations in paediatric- (10 of 130 patients)
compared with adult-onset (0 of 178 patients) IPAH patients. In comparison to BMPR2 mutation
carriers, TBX4 carriers had a 20-year younger age of onset, with a mean age of onset of 28.2 ± 15.4 years
and 7.9 ± 9.0, respectively. After BMPR2 mutations (10%), variants in TBX4 (7.7%) conferred the
highest degree of genetic risk of paediatric-onset IPAH [140]. Similar estimates of BMPR2 (12.5% of
I/FPAH patients) and TBX4 mutation carriers (7.5% of I/FPAH patients) were observed in a study
of 66 paediatric patients [141]. Additionally, in a 2019 study, examining 263 PAH and PVOD/PCH
patients (paediatric and adult cases), TBX4 mutations were the second most frequent mutations after
BMPR2 in both paediatric and adult cases [114].
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Indicative of bimodal age distribution, pathogenic TBX4 variants have also been reported in
adult-onset PAH. Gräf et al. [24] identified deleterious heterozygous rare variants in 14 cases, Navas
Tejedor et al. [120], in a Spanish cohort of 136 adult-onset PAH patients, identified three pathogenic
mutations, and Kerstjens-Frederikse et al. [108], in a much smaller adult cohort (n = 49), detected a
rare TBX4 mutation. In a more recent study, 448 index patients were screened for PAH predisposing
genes; 20 patients (nine childhood-onset) from 17 unrelated families carried heterozygous mutations in
the TBX4 gene, bringing the frequency of TBX4 mutations in France to 6% and 3% in childhood- and
adult-onset PAH, respectively [142]. Within this cohort, SPS was present in 80% of cases [142] and
interestingly, all patients showed decreased DLCO and 87% had parenchymal abnormalities. These
findings suggest that TBX4 mutations may occur with or without skeletal abnormalities and whilst
such mutations are mainly associated with childhood-onset PAH, the prevalence of PAH in adult TBX4
mutation carriers could be up to 3%, depending on the population studied.
A recent study of 1038 PAH patients observed that rare heterozygous variants in SOX17 were
significantly overrepresented in the I/HPAH cohort [24]. SOX17 is a member of the conserved
SOX family of transcription factors. These transcription factors play a pivotal role in cardiovascular
development and figure prominently in the aetiology of human vascular disease; they are involved in the
regulation of embryonic development, the determination of cell fate and participate in vasculogenesis
and remodelling [202]. In the NBR study [24], deleterious variants in SOX17 were detected in less than
1% of the studied population and were characterised by younger age at diagnosis; familial segregation
was shown in one patient.
To identify novel genetic causes of PAH-CHD, Zhu et al. [75] performed WES in 256 PAH-CHD
patients; the cohort included 15 familial and 241 sporadic cases. Fifty-six percent of the cohort were of
European ancestry and 26% were Hispanic; most cases (56%) had an age of onset < 18 years and so
were categorised as paediatric-onset. The cohort was screened for 11 known risk genes for PAH and
253 candidate risk genes for CHD; PAH risk variants were identified in only 6.4% of sporadic PAH-CHD
cases and four of the 15 familial cases. They performed a case-control gene-based association test of
rare deleterious variants comparing European cases and controls (gnomAD: n = 7509 non-Finnish
Europeans) and identified SOX17 as a novel PAH-CHD candidate risk gene [75]. They estimated that
rare deleterious variants in SOX17 contributed to approximately 3% of European PAH-CHD patients.
Following this discovery, they screened for SOX17 variants in non-European cases and an additional
cohort of PAH patients without CHD (n = 413) and identified five additional rare variants in the
PAH-CHD cohort and three additional rare variants in the I/HPAH cohort [75]. In this second cohort,
rare deleterious variants in SOX17 were observed in 0.7% of cases. In total, 13 patients across the two
cohorts were observed to have rare deleterious SOX17 variants; nine of these had paediatric-onset
PAH, suggesting these variants may be enriched in paediatric patients.
A Japanese study also demonstrated familial segregation of SOX17 variants [112]. This study
whole-exome sequenced 12 patients with PAH, 12 asymptomatic family members and 128 index cases
and identified SOX17 mutations in four PAH patients (three of these had congenital heart defects, i.e.,
atrial septal defect or patent ductus arteriosus) and one asymptomatic family member. Interestingly,
the same heterozygous missense mutation in SOX17 (c.397C) was observed in a Japanese patient [112]
and in a patient with PAH from the NBR study [24], suggesting that this base position may be a
pan-ethnic mutational hot spot. Taken together, these data strongly implicate SOX17 as a new risk
gene for PAH-CHD and suggest that this gene has a pleiotropic effect. Replication analyses in other
PAH cohorts, with specific PAH subclasses, are needed to confirm the precise role of SOX17.
New Genes
In recent years, new risk genes for PAH have emerged from large WES and WGS studies. Zhu
et al. [25] performed targeted gene sequencing alongside WES in a large cohort from the National
Biological Sample and Data Repository for PAH (US PAH Biobank: n = 2572). Despite screening
for 11 established PAH risk genes and seven recently reported risk genes, they failed to identify
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rare deleterious variants in known risk genes for 86% of the PAH Biobank cases (Group 1 PAH).
They performed gene-based case-control association analysis and to prevent confounding by genetic
ancestry, only participants of European ancestry (cases: n = 1832; controls: n = 7509 gnomAD
WGS subjects and n = 5262 unaffected parents from the Pediatric Cardiac Genomics Consortium)
were included. Using a variable threshold method, they identified two genes that exceeded the
Bonferroni-corrected cut-off for significance: BMPR2 and KLK1. KLK1, which encodes kallikrein 1,
also known as tissue kallikrein, has not previously been associated with pulmonary hypertension.
The analysis was then repeated using 812 European IPAH cases and significant associations were
observed for BMPR2, KLK1 and GGCX. GGCX encodes γ-glutamyl carboxylase and has previously
been implicated in coagulation factor deficiencies and vascular calcification [203], but again, never in
PAH. In a final analysis, the entire PAH Biobank cohort was screened for rare deleterious variants in
KLK1 and GGCX; twelve cases carried KLK1 variants (all European), whereas 28 cases carried GGCX
variants (19 European, six African, three Hispanic), accounting for ~0.4% and ~0.9% of PAH Biobank
cases, respectively. Carriers of KLK1 and GGCX had a later mean age of onset and relatively moderate
disease phenotype compared to BMPR2 carriers. Both KLK1 and GGCX, expressed in the lung and
vascular tissues, play an important role in vascular haemodynamics and inflammation. Whilst Zhu et
al. [25] identified KLK1 and GGCX as new candidate risk genes for IPAH, suggesting new pathogenic
mechanisms outside of the TGF-β/BMP signalling pathway, further research needs to be conducted to
better understand these findings, especially in larger cohorts of similar phenotypic characteristics.
In a recent large-scale analysis utilising the 13,037 participants enrolled in the NBR study, of
which 1148 patients were recruited to the PAH domain, we discovered KDR as a novel PAH candidate
gene [24,30] utilising the Bayesian model comparison method, BeviMed [64], and deep phenotype data.
Under an autosomal dominant mode of inheritance, high impact variants in KDR were associated with
a significantly reduced KCO (transfer coefficient for carbon monoxide) and older age at diagnosis [30].
Six ultra-rare high impact variants in KDR were identified in the study cohort; four of these were in
unrelated PAH cases, one in a relative and one nonsense variant was identified in a non-PAH control
subject. The latter variant appeared late in the protein sequence and hence might not impair protein
structure. To seek further evidence for KDR as a new candidate gene for PAH, we analysed subjects
recruited to two cohorts with similar phenotypic characteristics (US PAH Biobank: n = 2572; Columbia
University Medical Center: n = 440); four additional individuals harbouring rare high impact KDR
variants were identified, with one variant identified in both cohorts. A combined analysis of both
cohorts confirmed the association of KDR with PAH. Further evidence came from a French cohort of
311 PAH patients prospectively analysed by targeted panel sequencing (which included KDR) [117].
Two index cases with severe PAH, from two different families, were found to carry LoF mutations in
KDR, providing further genetic evidence for considering KDR as a newly identified PAH-causing gene.
Across both studies [30,117], there are now three reported familial cases with a distinct phenotype in
which LoF variants in KDR segregate with PAH and significantly reduced KCO.
Power to detect novel genotype–phenotype associations can be increased by merging existing
datasets, aligning sequences to the most recent genome assembly, using the most up to date reference
variome, and improved variant classification tools, as well as updated clinical phenotypes. Such an
approach was recently taken by a large international consortium of 4241 PAH cases from three cohorts
(US PAH Biobank: n = 2572; Columbia University Medical Center: n = 469; NBR: n = 1134). Of the
available 4175 sequenced exomes, most cases (92.6%) were adult-onset, with 54.6% IPAH, 34.8% APAH,
5.9% FPAH and 4.6% other; 74.5% of the cohort was European [118]. Gene-based case-control
association analysis in unrelated participants of European ancestry was performed, using 2789 cases
and 18,819 controls taken from the Simons Foundation Powering Autism Research for Knowledge
(SPARK) cohort and gnomAD, before screening the whole cohort, including non-Europeans, for rare
deleterious variants in associated genes. Statistical analyses revealed that rare predicted deleterious
variants in seven genes were significantly associated with IPAH, including three established PAH risk
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genes (BMPR2, GDF2, and TBX4), two recently identified candidate genes (SOX17 and KDR) and two
new candidate genes (FBLN2 and PDGFD).
Both new candidate genes have known functions in vasculogenesis and remodelling but have
not previously been implicated in PAH. In total, they identified seven cases with FBLN2 variants and
ten cases with PDGFD variants, accounting for 0.26% and 0.35% of IPAH cases, respectively; most of
these were of European ancestry and all were adult-onset, except for one paediatric PDGFD variant
carrier. Analysis of single-cell RNAseq data showed that FBLN2 and PDGFD have similar expression
patterns to well-known PAH risk genes [118]. Whilst this provides additional support and mechanistic
insight for the new genes, as with the discovery of KLK1 and GGCX, variants within FBLN2 and PDGFD
require independent validation.
Autosomal Recessive Mode of Inheritance
PVOD/PCH has recently been reclassified as an ultra-rare form of Group 1 PAH [18]. PVOD
and PCH often show significant phenotypic overlap. Indeed, 73% of patients diagnosed with PVOD
are found to have capillary proliferation and 80% of patients with PCH demonstrate typical venous
and arterial changes [204], and are, therefore, referred to as PVOD/PCH. Clinically, PVOD/PCH is
characterised by early-onset, significantly reduced DLCO and patchy centrilobular ground-glass
opacities, septal lines and lymph node enlargement seen on high-resolution computed tomography.
The disease outcome is dismal, with rapid progression and frequent pulmonary oedema in response
to PAH medication. Similarly to PAH, PVOD/PCH can present as either a sporadic or familial
disease [205,206]. It was the latter that triggered a family-based study into the genetic basis of this
condition. Familial linkage mapping, WES, and Sanger sequencing were employed and identified
biallelic EIF2AK4 mutations in affected siblings. Subsequently, biallelic EIF2AK4 mutations were
also identified in 25% of sporadic PVOD cases [109], 11.1% of HPAH cases (one of nine cases) [110]
and 1.04% of I/HPAH cases (nine of 864 cases) [111]. Harbouring EIF2AK4 mutations confer a poor
prognosis irrespective of clinical diagnosis and importantly, radiological assessments were unable to
distinguish reliably between PVOD/PCH patients and patients with IPAH [111].
4.3.2. Common Genetic Variation
Complex pathobiology, low penetrance, heterogeneous phenotype and variable disease trajectory
allow for common sequence variation that contributes to PAH risk and natural history. In HPAH,
several common genetic variants were shown to impact the disease. Firstly, BMPR2 mutations are
a significant source of sex-related bias in disease penetrance (42% in females vs 14% in males) [122];
one explanation for this could be gene polymorphisms involved in estrogen metabolism [207]. Females
harbouring deleterious variants in BMPR2 show a significant reduction in CYP1B1 gene expression
and as a consequence, a lower 2-hydroxyestrone to 16α-hydroxyestrone ratio leading to activation of
mitogenic pathways [207]. Moreover, direct estrogen receptor α binding to BMPR2 promoter results
in reduced BMPR2 gene expression in females and may contribute to the increased prevalence of
PAH [208]. Secondly, variation in BMPR2 expression in HPAH, caused by nonsense-mediated decay
positive (NMD+) BMPR2 mutations, is conditional upon individual polymorphisms of the wild type
(WT) allele [209]. Thirdly, a SNP in TGFβ1 modulates age at disease onset in patients harbouring
BMPR2 mutations [210].
In IPAH, a SNP (rs11246020) in the Sirtuin3 (SIRT3), mitochondrial deacetylase, in either
homozygote or heterozygote fashion, was associated with increased acetylation of mitochondrial
proteins compared to the IPAH patients or disease comparator group with the WT genotype [166].
SIRT3, by deacetylating and thus activating multiple enzymes and electron transport chain complexes,
plays a significant role in cell bioenergetics, and its polymorphism has been associated with
susceptibility to metabolic syndrome [211] and IPAH, but not APAH [166]. Similarly, uncoupling
protein 2 (UCP2), shown to conduct calcium from the endoplasmic reticulum (ER) to mitochondria
and suppressing mitochondrial function, has been implicated in the pathogenesis of PAH [168].
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These findings have important therapeutic implications as common variants in SIRT3 and UCP2
predicted response to dichloroacetate, pyruvate dehydrogenase kinase inhibitor, in a PAH phase
2 clinical trial [167]. Renin–angiotensin–aldosterone (RAA) system has been implicated in the
pathogenesis of both systemic and pulmonary hypertension. For example, polymorphisms in the
gene encoding angiotensin-converting enzyme (ACE) have been associated with IPAH [212] and with
diaphragmatic hernia with persistent pulmonary hypertension [213]. Likewise, common variation in
angiotensin II type 1 receptor (AGTR1) was associated with age at diagnosis in PAH. These findings
indicate that RAA might be a therapeutic target [34].
Considering the important role of vasoactive, angiogenic and angiostatic substances in the
pathogenesis and therapy of PAH, studies investigating the impact of common variation on gene
expression of these substances are warranted. Recently, Villar et al. [170] found a recurrent SNP
(rs397751713) in the promoter region of the endothelin-1 (END1) gene that had important regulatory
consequences in both IPAH and APAH patients; rs397751713, which consists of an adenine deletion,
allows transcription factors (Peroxisome proliferator-activated receptor γ (PPARG) and Kruppel Like
Factor 4 (KLF4)) to bind to the promoter. Both of these transcription factors are linked to PAH
pathogenesis and have been suggested as potential therapeutic targets [214–217]. In a similar fashion,
a polymorphism in a potent angiostatic factor, endostatin, Collagen Type XVIII α 1 Chain (Col18a1),
was studied. A SNP (rs12483377) in Col18a1 was observed at an increased frequency in PAH patients
(MAF 21.6) relative to published controls (MAF 7.5), or patients with scleroderma without PAH
(MAF 12.5). Rs12483377 encodes uncharged amino acid asparagine (N) at residue 104 in place of
negatively charged aspartic acid (D); carriers of single minor allele A (genotype AG), had lower serum
endostatin levels than those who carried WT (genotype GG) and showed better survival even after
adjusting for confounders [173].
Along with studies looking at polymorphisms in a particular gene or its promoter region, two
GWAS have been carried out in PAH. The first consisted of a discovery and validation cohort totalling
625 patients (sans BMPR2 mutations) and 1525 healthy individuals. A genome-wide significant
association was found at Cerebellin 2 Precursor (CBLN2) locus; rs2217560-G allele was more frequent
in cases than in controls in both the discovery and validation cohorts with a combined odds ratio (OR)
for I/HPAH of 1.97 [95% CI 1.59;2.45] (p-value 7.47 × 10−7). Although the rs2217560 genotype did
not correlate with CBLN2 mRNA expression in monocytes, higher CBLN2 mRNA levels were seen in
lung tissue explanted from PAH patients than in control lung samples. Further analysis showed that
increasing concentrations of CBLN2 lead to inhibition of proliferation of PASMCs [165].
To date, the largest PAH GWAS of multiple international I/HPAH cohorts, totalling 2085 cases and
9659 controls, identified two novel loci associated with PAH: an enhancer near SOX17 (rs10103692,
OR 1.80 (95% CI 1.55;2.08), p = 5.13 × 10–15), and a locus within HLA-DPA1/DPB1 (rs2856830, OR 1.56
(95% CI 1.42;1.71), p = 7.65 × 10–20) [116]. CRISPR-mediated inhibition of the enhancer reduced SOX17
expression; this finding corroborates and extends the previous discovery of the association of rare
variants in SOX17 with PAH [24]. The HLA-DPA1/DPB1 rs2856830 genotype was not only associated
with I/HPAH but also with a beneficial effect on survival (CC genotype 13.5 vs TT genotype 6.97 years)
irrespective of baseline disease severity, age and sex [116]. The latter study did not replicate previous
results at genome-wide significance.
4.4. Limitations, Challenges and Future Directions
The major limitations in PAH genetic studies originate from either their study design or the genetic
methods used. The former is mostly limited by sample size and population structure and features in
GWAS and RVAS alike, the latter is impacted by sequencing technology, genome assembly and analysis
pipelines. Additionally, the variable quality of reporting may obscure the validity of the results. Several
approaches may accelerate causal variant discovery. Firstly, international efforts to set up platforms
and governance, thereby reducing the barriers to genotype and phenotype data harmonisation, across
studies and countries, along with regulatory standards, compatible with the international legislative
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landscape, aid variant discovery. Secondly, the application of computational and/or intermediate
phenotypes may further increase power to detect new risk genes. Likewise, researching isolated
populations resulting from recent bottlenecks (i.e., Icelanders, Ashkenazi Jews) have shown promising
results in other rare diseases. As for genetic methods, long-read technologies will improve significantly
and with improvements to the error rate, long-read alignment to a pan-genome graph may identify
additional genetic variants. Expansion of resources for allele frequency estimation (i.e., gnomAD),
encompassing diverse ethnicities and variant classes, including structural variants, will improve
variant interpretation. Studying gene sets that are likely to be enriched for disease-associated loci (i.e.,
implicated by GWAS, or expressed in disease relevant tissues) and extending RVAS to non-coding
regions (a natural step given GWAS findings) is likely to further increase discovery yield.
5. Reverse Genetics
5.1. Concepts
Reverse genetic techniques have been used extensively in the context of PAH. These experimental
approaches involve targeted modifications to specific genes in order to analyse phenotypic impact
(Figure 1, process 3) and are critical in validating in silico predictions. Most deleterious mutations
found in PAH patients are LoF, suggesting a knockout or knockdown approach to analysing the
phenotypic effect of a mutation. The main benefit of direct gene mutagenesis is the permanence and
potentially ubiquitous effect of that alteration. In comparison, gene knockdown is a transient change
that can be created after the developmental stage in the animal life cycle. This is particularly useful for
understanding LoF in genes that are embryonically lethal [123]. Conditional and inducible systems
are also excellent means of circumventing this issue, permitting temporally and spatially controlled
gene disruption [55,125,128,218]. Inducible systems display higher efficiency and limited side effects
compared to stably-expressed mutations and have the added benefit of reversibility [219].
5.2. Methodology
Techniques for genetic modification have permitted targeted genetic analysis using in vitro and
in vivo models of PAH. Modification of a specific gene, through mutagenesis or knockout, can be carried
out using a wide range of tools, including Zinc-finger nucleases (ZFNs) [220], transcription activator-like
effector nucleases (TALENs) [221], and CRISPR/Cas9 [222]. Similarly, transient genetic changes can be
achieved through gene expression knockdown, such as RNAi [223], or using conditional/inducible
expression systems, such as Cre/LoxP and Flp/FRT sites or the Tet inducible system [224]. Generating
models with specific mutations is also critical for the identification of therapeutic targets and drug
testing. Specific techniques and their utility in animal models have been extensively reviewed [224–226].
5.2.1. In Vitro
As PAH is a disease of the pulmonary circulation, most studies seek to model genetic changes
in physiologically relevant cell lines. This includes pulmonary artery endothelial cells (PAECs),
PASMCs, blood outgrowth endothelial cells (BOECs) [227] and human umbilical vein endothelial
cells (HUVECs). PAH is characterised by molecular and cellular deviations in pulmonary vascular
function [228,229], including hyperproliferation [124,129,130,149], impaired migration [127,130,150]
and aberrant apoptosis [124,230]. Traditionally, research has focused on using 2D cellular monolayers
for analysis of these features; however, with rapidly evolving technologies, future analysis may utilise
multi-layer, 3D models such as organoids [231] and hydrogels [232] to better replicate the pathobiology
of PAH.
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5.2.2. In Vivo
Understanding the pathobiology of PAH is dependent upon robust animal models for functional
analysis and exploration of potential therapeutics. To achieve this aim, a wide range of animal models
have been developed across species, including pig, sheep, dog and most commonly rodents [233].
The most widely accepted rat models for PAH are pharmacologically induced, namely
monocrotaline (MCT) and Sugen 5416-hypoxia (SuHx) models [234]. MCT is a toxin that induces
damage to PAECs, causes RV and pulmonary arterial medial hypertrophy, and alters pulmonary
artery pressures [235,236]. In the SuHx rat model, SU5416, a Vascular Endothelial Growth Factor
Receptor (VEGFR) antagonist that promotes endothelial cell apoptosis and smooth muscle cell (SMC)
proliferation [237], is administered followed by a period of hypoxia [234]. SU5416 requires hypoxia
to induce severe PAH, causing vascular changes that model human IPAH [237]. Both models induce
non-PAH related symptoms, including alveolar oedema, pulmonary vein occlusion, acute lung injury,
liver toxicity and emphysema [238,239].
The chronic hypoxia mouse model is also widely used in PAH research, with mice housed at
10% oxygen for a variable length of time [234,240,241]. While mice display changes in pulmonary
artery pressure, they display limited vascular remodelling, which consists of muscularization of
vessels and medial hypertrophy of muscular resistance vessels [242]. Alternatively, pulmonary artery
banding (PAB) has been used in various species to increase pulmonary artery pressures and induce
RV hypertrophy. The main benefit of this technique is the lack of pharmacologic or environmental
modification of the animal [243]. In practicality, the popularity of each model varies across PAH
research groups; a recent poll showed that two-thirds of groups used two or more models [244],
suggesting that no one model truly replicates the disease.
In comparison, genetic models tend to be more favourable as they are free from the systemic effects
of pharmacological models. Several heterozygous BMPR2 mutant models have been developed. While
some models have shown elevated mPAP and PVR compared to WT littermates [123], others did not
replicate these findings [245,246]. Alternate studies have shown the development of pulmonary vascular
lesions [126] and often, an environment hit may be required for development of PAH [131,245,246].
More pronounced phenotypes are seen in homozygous deletions; as BMPR2 is critical for embryogenesis,
conditional deletion in pulmonary endothelial cells has been used and showed incomplete penetrance of
the mutation, with a subset of mice displaying elevated RVSP, RV hypertrophy and inflammation [125].
The following genetic models have also been developed: KDR (cell-specific conditional deletion
of Kdr in mice) [155], AQP1 (Aqp1 null mice [151] and Aqp1 with a COOH-terminal tail deletion [149]),
TET2 (conditional, haematopoietic heterozygous and homozygous deletion in mice, generated using
the Vav1-Cre system) [55], BMPR1a (several conditional knockout mice models) [156,157,159], SOX17
(conditional deletion in mice, using Demo1-Cre in descendants of the splanchnic mesenchyme) [153],
UCP2 (knockout mouse model created using a plasmid vector carrying modified Ucp2) [169],
CAV1 (modified mouse cav-1 targeting construct) [138], EIF2AK4 (modified mouse Gcn2 targeting
construct) [164], SIRT3 (heterozygous and homozygous mice, generated using targeted embryonic
stem cell clones harbouring a mutated SIRT3) [166], ATP13A3 (generation of a protein truncating
mutation in mouse Atp13a3 using CRISPR/Cas9) [147], SMAD9 (Disrupted Smad8 allele generated
in mice using LoxP/cre and Frt sites) [134], KCNK3 (heterozygous and homozygous rats harbouring
a CRISPR/Cas9-generated exonic, inframe deletion) [146] and SMAD1 (mice with Smad1 deletion in
endothelial cells or SMCs, generated using L1Cre or Tagln-Cre, respectively) [136].
In humans, the severity of disease corresponds to the extent of pulmonary vascular changes and
impairment of RV function. However, rodent models may display milder and isolated symptoms of
PAH and, thus, require thorough characterisation to validate the model. Echocardiography is useful for
the assessment of RV function but estimates of pulmonary pressures are inferior to direct measurements
obtained through RHC [234]. Alternatively, cardiac magnetic resonance imaging is another noninvasive
tool for assessment of RV function; it supersedes echocardiography in its ability to produce high quality,
three-dimensional images from which the RV can be directly measured. However, it also has limited
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availability and bears higher running costs [247]. Close-chested RHC is preferred over open-chested
RHC, as it is less invasive and preserves the negative intrathoracic pressure associated with breathing.
Open-chested RHC is usually a terminal procedure, thus preventing longitudinal assessment of rodents;
however, it also permits a more comprehensive assessment of haemodynamic characteristics and
analysis using pressure–volume loops. Tissue harvesting permits further characterisation of the heart
and lungs, including evaluation of RV hypertrophy [234].
It is important that measures are taken to recognise and limit bias in experimentation and
phenotyping. This includes ensuring randomisation of groups when carrying out tests that require
a control and treatment group, such as selecting mice to be pharmacological models or therapeutic
treatment. Additionally, mice should be matched for all possible qualities, including strain, age and
sex. During phenotype assessment, researchers should aim to avoid implicit bias by using blinded
observers during all procedures. Furthermore, the data collected must be comprehensive and relevant
for PAH, including RHC data and histological analysis [248].
5.3. Studies
5.3.1. Rare Genetic Variation
Autosomal Dominant Mode of Inheritance
TGF-β Family
BMPR2, a receptor in the TGF-β pathway, is the most commonly mutated gene in PAH. BMP
ligands induce signalling through binding with BMPR2 and ALK 1, 2, 3 or 6 to induce downstream
SMAD-mediated transcription [249]. This pathway plays important roles in cell proliferation,
differentiation, migration, apoptosis and inflammation, which are often dysregulated in PAH. Alongside
BMPR2, several pathway components have been implicated in disease; this includes the ALK and
SMAD proteins, as well as coreceptors, such as endoglin [250]. Reverse genetics techniques have
been used extensively on these genes to understand their role in PAH and their interaction with other
members of the pathway. BMPR2 has been extensively analysed using the methods described; under
normal conditions it is highly expressed in vascular ECs, with lower levels of expression in SMC;
however, reduced levels have been reported in the lungs of PAH patients [181]. In the endothelium,
BMP9 and BMP10 induce binding of BMPR2 and ALK1, along with co-receptor endoglin, to induce
downstream signalling. Such signalling is often disrupted in HPAH patients that harbour mutations in
BMPR2 [251]. However, disruption of BMP-mediated signalling is also apparent in IPAH patients,
despite the absence of BMPR2 mutation [252].
Gene disruption and knockout techniques have been key to elucidating the role of BMPR2 in
pathogenesis. Such techniques have revealed dysregulation of endothelial nitric oxide synthase (eNOS)
in cell culture models of PAH; siRNA-mediated knockdown of BMPR2 induced endothelial dysfunction
in human PAECs, caused by a reduction in BMP2/4-mediated production of the vasodilator nitric oxide
by eNOS [127]. In addition, reduced BMPR2 has been associated with overactive glycolysis [130] and
hyperproliferation [124].
Furthermore, a key feature of PAH is incomplete penetrance in BMPR2 mutation carriers. This has
been replicated in mice carrying conditional knockout mutations of Bmpr2 in pulmonary endothelial
cells, with only a proportion of mice developing haemodynamic symptoms of PAH [125]. In addition,
it has been shown that BMPR2 mutations disrupt RV function, with heterozygous mice displaying
impaired hypertrophy and lipid accumulation in the RV [128]. Moreover, EndoMT has been suggested
to be a characteristic of PAH in both animal models and patients [253,254]. This includes a heterozygous
BMPR2 mutant rat model, which displayed overexpression of two molecular markers of EndoMT.
Such changes were also seen in PAH patients when analysing mRNA and protein level changes in
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lung and artery tissue [129]. These in vivo models have therapeutic utility, having been used to test
treatments that include rapamycin [129] and metformin [128] to alleviate symptoms.
The experimental techniques discussed have been highly important in identifying other members
of the TGF-β pathway that are implicated in PAH pathogenesis. This includes the Smad proteins, for
which functional evidence is limited. Functional analysis of variants detected in SMAD1, SMAD4
and SMAD9, have shown impaired signalling in Smad4 and Smad9. However, variants only have a
moderate impact on phenotype, suggesting further genetic or environmental hits may be required to
induce PAH [54]. Furthermore, analysis of CAV1 mutations have revealed impaired protein trafficking
in mouse embryonic fibroblasts carrying a disrupted copy of CAV1. Furthermore, patient fibroblast
cells displayed reductions in both CAV1 and associated accessory proteins [137]. Thrombospondin 1
(THBS1) mutants, which regulate TGFβ function, have been found to have impaired ability to activate
TGFβ, and permit proliferation of PASMCs. Additionally, an electrophoretic mobility shift assay
(EMSA) was used to analyse the binding of biotin labelled oligonucleotides with two transcription
factors, MAZ and SP1, showing a reduction in efficiency [174].
As previously discussed, GDF2, encoding the ligand BMP9, is critical in BMPR2-mediated
signalling in endothelial cells. Functional studies are particularly important in validating in silico
predictions regarding the pathogenicity of certain variants. Hodgson et al. [115] analysed seven missense
mutations in GDF2, which had been previously associated with PAH and predicted pathogenic in silico.
When analysed in vitro, all variants displayed dysfunctional processing, secretion or protein stability. In
addition, functional studies found a predicted benign mutation to be deleterious. Similarly, association
analysis in IPAH patients of Chinese Han ethnicity identified GDF2 mutations [26]. Six mutations were
selected for functional studies, using mutant GDF2 plasmids transfected into HEK293E cells/PAECs.
Mutants displayed reduced BMP9 levels, reduced BMP activity and increased apoptosis [26].
There is some evidence implicating BMPR1A, which encodes the type I receptor ALK3, in PAH.
A hypoxia mouse model harbouring a mosaic deletion of Bmpr1a, generated through conditional
deletion of the gene in SMCs using the TRE-Cre system, displayed proximal artery stiffening caused by
excess collagen. This may lead to constricted vessels and impairment of right ventricular function [255].
Furthermore, two independent studies have implicated reduced Bmpr1a expression with EndoMT
and shown that the phenotype may be rescued by attenuating expression of TGFBR2, which is
upregulated in the mice models [156,157]. Additionally, functional analysis of BMPR1B mutations
found in PAH patients found changes in transcriptional activity, which resulted in increased SMAD8
phosphorylation [160].
Channelopathies
Alongside TGFβ-family members, various channel proteins have been linked to pathogenesis.
Functional analysis was conducted on six mutations reported in KCNK3, all of which resulted in LoF.
Patch clamp variants showed a reduction in current, with rescue of channel function, in a subset
of variants by administration of a phospholipase inhibitor, ONO-RS-082 [107]. In addition, Bohnen
et al. [145] introduced a heterozygous, single amino acid variant into KCNK3 using site-directed
mutagenesis and transfected hPASMCs with this mutant via a pcDNA3.1 plasmid. The physiological
impact of this mutation was assessed using whole-patch clamp tests to observe changes to membrane
potential and current, with experiments demonstrating loss of channel function in mutant cells
compared to WT KCNK3. More limited evidence is available for the role of ATP13A3, a P-type ATPase,
in PAH; siRNA-mediated knockdown of expression resulted in a reduction in cell proliferation and
increased apoptosis, as well as the loss of endothelial integrity in hPAECs [230]. Furthermore, mutant
ATP13A3 mice, carrying a protein-truncating variant introduced using CRISPR/Cas9, demonstrated
haemodynamic measurements indicative of PAH. This included reduced pulmonary artery acceleration
time (PAAT) and increased RVSP, with rats also exhibiting reduced polyamine levels in their lungs [147].
AQP1 has been associated with cell migration and vascularity. AQP1 is highly expressed in
microvascular endothelial cells, vascular smooth muscle cells and non-vascular endothelium [256],
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and has recently been proposed as a novel promoter of tumour angiogenesis [257]. A recent study
demonstrated that depletion of AQP1 reduced proliferation, migratory potential, and increased
apoptosis of PASMCs [258]. Saadoun et al. [150] produced an AQP1 knockout mouse model using
targeted gene disruption; when implanted with melanoma cells, the developing tumours displayed
impaired angiogenesis. In-depth analysis of APQ1 function in endothelial cells, produced from mouse
aortic cells, using cell migration, wound healing, proliferation and cord development assays, revealed
critical roles of AQP1 in cell migration. AQP1 null cells showed reduced ability in all four assays.
This was corroborated by the plasmid expression of AQP1 and another water channel protein, AQP4,
in non-endothelial cells, resulting in increased migration. Functional analysis has confirmed the role of
AQP1 in cell migration under hypoxic conditions. Yun et al. [149] used rat pulmonary-artery-derived
PASMCs, infected with adenovirus vectors carrying either WT AQP1 or AQP1 with a 37 amino acid
terminal deletion removing the COOH tail. Overexpression of AQP1 increased levels of β-catenin and
its downstream targets, including c-Myc and cyclin D1. However, loss of the COOH tail produced
no such results, suggesting COOH-mediated upregulation of β-catenin. Both AQP1 and β-catenin
displayed elevated levels under hypoxic conditions. This was further corroborated by siRNA-mediated
silencing of β-catenin, in cells subject to hypoxia, and consequent infection with adenoviral constructs.
Cells were rescued from the migration and proliferation associated with hypoxic conditions.
Additionally, functional analysis has been conducted on ABCC8. Eight mutations were analysed
in COS cells using patch-clamp tests and rubidium flux assays, as a measure of ion efflux. Loss of
channel function was seen in all variants, with the rescue of function by the administration of the SUR1
activator drug, diazoxide [113]. Additionally, functional analysis of KCNA5, by overexpressing the
gene in PASMCs, showed an increase in channel current that was rescued by administering either
nicotine, bepridil, correolide or endothelin-1 [163]. Additional genes have been reported, but have
limited functional evidence confirming their role in PAH. One such gene is UCP2, encoding uncoupling
protein 2, which functions as a calcium channel in vascular mitochondria that mediates ion influx from
the ER. Fluorescence resonance energy transfer imaging of mitochondria from resistance pulmonary
arteries of mice harbouring a Ucp2 knockout showed a reduced calcium concentration, impairing their
function, and mimicking the effects of hypoxia. Impaired mitochondrial function has been associated
with the hyperproliferative and anti-apoptotic symptoms seen in PH [168]. Another channel protein is
TRPC6. Using Western blot analysis, TRPC6 was found to be upregulated in PASMCs obtained from
IPAH patients, compared to control cells. The endothelin receptor antagonist, Bosentan, was found
to act by downregulating TRPC6 and had a more pronounced anti-proliferative effect on IPAH cells
than on WT cells [259]. Alternatively, potassium channel function has been rescued using adenoviral
infection of human Kv1.5, into mice exposed to chronic hypoxia for three to four weeks. Mice were
alleviated of hypoxia-induced vasoconstriction, displaying reduced right ventricle and pulmonary
artery medial hypertrophy, when compared to control mice subject to hypoxia [260].
Transcription Factors
TBX4 is an evolutionarily conserved transcription factor, which plays a critical role in limb
development during embryogenesis [261]. Detection of a lung-specific Tbx4 enhancer, specific
to the lung mesenchyme and trachea during embryogenesis, suggest an important role in lung
development [262]. It has been shown to induce myofibroblast proliferation and drive invasion of
the matrix by fibroblasts, promoting the development of pulmonary fibrosis, and deletion of Tbx4 has
led to a reduction in fibrosis [262]. TBX4 plays a role in lung development and has been linked to
pulmonary fibrosis, suggesting a possible role in PAH; nonetheless, experimental evidence is required
to confirm this. Similarly, SOX17 has been shown to be critical for the development of pulmonary
vasculature. A mouse model, harbouring a conditional deletion of Sox17 in splanchnic mesenchyme
descendants, displayed impaired pulmonary vascular development leading to death by three weeks of
age [153]. Shih et al. [154] assessed the role of SOX17 using siRNA-mediated knockdown of expression
in PAECs, followed by angiogenesis assays that showed impaired vessel formation. Concurrently,
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a mutant SOX17 cell line, generated through CRISPR/Cas9 mutagenesis of human iPSC, showed a
reduction in expression of arterial genes compared to WT cells.
New Genes
More recently, a plethora of new genes have been found to harbour mutations in PAH patients;
however, functional evidence for their involvement remains limited. TET2, involved in DNA
demethylation, is a key epigenetic regulator and has been found dysregulated in PAH. Potus et al. [55]
developed heterozygous and homozygous Tet2 knockout mice models, by crossing floxed Tet2 parents
and Vav1-cre to excise the gene. Their phenotype was ascertained through echocardiography and RHC.
Patients carrying TET2 mutations were found to have a later age of onset compared to other PAH
patients; this finding was replicated in mice. Genetic evidence has also implicated KDR in PAH; Winter
et al. [155] developed a mouse model with a conditional deletion of the KDR gene, encoding VEGFR2,
in endothelial cells. The mice developed mild PAH symptoms under normoxic conditions; however,
these were exacerbated under hypoxia with mice displaying pulmonary vascular remodelling.
Other genes which have been associated with PAH through sequencing analysis have no
functional evidence with respect to PAH; however, physiological functions reveal possible mechanistic
roles in the disease. GGCX has also been associated with PAH using forward genetics studies but
lacks any functional evidence to corroborate this. This gene encodes a protein that carboxylates
glutamate residues on Vitamin-K-dependent proteins; these are vital for the activation of coagulation
proteins [263], inhibiting vascular calcification and inflammation [25]. Mutations in GGCX have been
associated with Vitamin-K-dependent clotting factors deficiency, a congenital bleeding disorder [264]
and Pseudoxanthoma elasticum [265].
Additionally, KLK1 plays a key role in cardiac and renal function, notably regulating blood
pressure. Kinins are known to affect endothelial cells, especially playing a role in vasodilation,
increasing vascular permeability, nitric oxide production and inflammation. Tissue kallikrein is
highly expressed in the kidney, pancreas, central nervous system and blood vessels [266]. Kinins,
which include bradykinin, are regulated by inactivating enzymes known as kininases, of which the
ACE is the most well known [267]; ACE-inhibitors are effectively used to reduce blood pressure [268].
Indeed, hypertension has been associated with polymorphisms and deficiencies in KLK1 expression in
rat models [269,270]. While genetic variation in KLK1 has been associated with essential hypertension
in a Chinese Han cohort [271], other studies have reported conflicting evidence on its role in the
condition [268]. Nonetheless, this gene and pathway offer potential therapeutic targets, having major
functions in areas of dysfunction seen in PAH, demonstrated by the evidence showing that KLK1 can
be used for its vasodilative properties in the treatment of acute ischemic stroke [272].
Autosomal Recessive Mode of Inheritance
Anthony et al. [273] demonstrated that homozygous Eif2ak4 knockout mice displayed increased
levels of protein carbonylation, a symptom of oxidative damage that was induced by dietary leucine
deprivation. Additionally, these mice exhibited reduced viability compared to controls, with some
dying shortly after birth. Their findings suggest that the gene may elicit protective effects against
oxidative damage.
5.3.2. Common Genetic Variation
Another interesting PH animal model is the Sirt3 knockout mice, which displays higher mPAP,
PVR, RV hypertrophy and reduced exercise tolerance, compared with controls. This gene has been
implicated in IPAH, with reduced expression in hPASMCs obtained from patients. The severity of
symptoms in the model occur in a dose dependent manner, with Sirt3 heterozygous mice displaying
milder symptoms than homozygous knockout mice. This includes the extent of muscularisation
and medial wall thickness of resistance PAs, which is more severe in homozygotes [166]. However,
another Sirt3KO mouse model, against a C57BL/6 background [274] failed to develop PH, which may
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be attributed to differences between the mouse strains used. The 129/Sv strain used by Paulin et
al. [166] possess a slower metabolism compared to C57BL/6 mice, which may mean loss of Sirt3 is more
damaging than in the latter strain.
Mutations in vasodilatory and vasoconstrictive proteins have been implicated in PAH, including
END-1. In situ hybridisation has shown END-1 upregulation in the lungs of patients with PAH, with
greatest abundance in vessels subject to disease-associated remodelling [171]. Furthermore, analysis of
a SNP found in the reporter region of END-1 using a luciferase assay has shown upregulated activity.
Homozygous mutants display a 30% increase in promoter activity and loss of binding of KLF4 and
PPAR γ, which have both been linked to PAH [170].
Common variation in the DNA Topoisomerase II Binding Protein 1 (TopBP1) has been found in
IPAH patients. Immunohistochemical analysis of vascular lesions demonstrated a reduction in TopBP1
protein. Analysis of cultured pulmonary microvascular endothelial cells from IPAH lungs, using
q-PCR and Western blotting, showed a reduction in TopBP1 mRNA and protein. Further analysis of
cells for increased susceptibility to DNA damage, by administering hydroxyurea and staining nuclei
for phosphorylated histone foci, revealed an excess of DNA strand breaks and apoptosis. However,
patient cells could be rescued by transfection with a plasmid containing wild-type human TopBP1,
displaying a reduction in DNA damage-induced apoptosis [172].
In addition, functional analysis has been completed in SOX17. A luciferase reporter construct was
generated for each haplotype of four heterozygous SOX17 mutations and transfected into hPAECs to
assess transcriptional activity [116,275]. Comparison of each haplotype revealed a haplotype-specific
difference in promoter activity in a subset of variants. Two variants showed a statistically significant
decrease in promoter activity in the risk allele, compared to the non-risk allele. Evidence exists for the
intricate function of the various genes implicated in PAH, including regulatory roles of SOX17. VEGF
has been shown to upregulate SOX17, while the Notch pathway plays critical roles in downregulating
Sox17 in the endothelium. Additionally, there is a positive feedback loop between VEGR and
SOX17 [275]. These findings support the evidence that a wide range of mutations across genes are
capable of eliciting similar phenotypic impacts through large-scale changes to pathway regulation.
5.4. Limitations, Challenges and Future Directions
To conclude, reverse genetics techniques are vital components of PAH research, without which
forward genetics’ discoveries cannot be validated. Nonetheless, it is important that such studies are
interrogated for any limitations that may affect their results. As previously mentioned, it is important
to have a robust experimental design and protocol, which includes power calculations for animal
studies, minimising bias and reporting all measurements in publications. Cellular models are powerful
in vitro tools for understanding specific processes in PAH; however, focusing on certain cell types may
produce more pronounced effects than those seen in vivo. Understanding the widespread impact of
PAH mutations are best captured using animal models. However, it is important to remember that
all fail to fully recapitulate the disease and that any toxic side effects of pharmacological models may
confound results. Studies must choose models which are most appropriate for the hypothesis, or use
multiple where necessary. Furthermore, focusing specifically on rodent models, these often capture
longitudinal data through the use of terminal procedures for haemodynamic measurements. The
experimental techniques discussed here are well established in the field; however, several new tools
have been developed which may increase the speed and depth of information derived using reverse
genetics; these include high-throughput technologies for mutagenesis and spatial gene expression
analysis [276,277]. Such developments offer exciting prospects for future research in PAH.
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6. Reverse Phenotyping
6.1. Concepts
The concept of reverse phenotyping (Figure 1, process 4) refers to the use of genetic marker
data to refine the disease subgroup definitions [36]. The method was first used in phenotyping
patients with sarcoidosis [278] and has proven successful in many other diseases characterised by
high heterogeneity [279].
6.2. Theoretical Basis
Heterogeneity provides a unique challenge in the diagnosis and treatment of rare diseases, and
is further complicated by the accuracy of reporting. Knowledge about the genetic makeup of the
individual allows targeted treatments, thereby enhancing efficacy and decreasing the risk of potential
side effects [280]. Conversely, knowledge about the phenotypic characteristics of mutation carriers is
indispensable to match study design and methodological approaches to disease attributes [281].
6.3. Methodology
Studying the complexity of genotype–phenotype associations is of particular interest to medical
genetics. Evidence for such studies can be retrieved from published peer-review literature and
publicly available databases, and facilitated by computational tools such as the R package VarformPDB
(Disease-Gene-Variant Relations Mining from the Public Databases and Literature), which captures
and compiles the genes and variants related to a disease, a phenotype or a clinical feature from
public databases including HPO (Human Phenotype Ontology), Orphanet, OMIM (Online Mendelian
Inheritance in Man), ClinVar, and UniProt (Universal Protein Resource) and PubMed abstracts.
Alternatively, the development of large biobanks that link rich electronic health record (EHR) data
and dense genetic information have made it possible to enhance clinical characterisation of mutation
carriers in a cost-effective fashion. Besides deep clinical, often longitudinal phenotyping, multi-omic
approaches can be employed thanks to the concurrent collection of patients’ biological samples.
A number of efforts have been made to facilitate EHR-based genetic and genomic research, such as the
establishment of the UK Biobank [282], the Electronic Medical Record and Genomics Network [283]
or the Precision Medicine Initiative Cohort Program [284], which allow both forward genetics and
reverse phenotyping applications. Mining EHRs for genetic research purposes possesses a number
of advantages over classical population or family-based genetic association studies, large samples
can be collected over a short period of time in a cost-effective fashion. Moreover, the robustness of
EHRs allows for the investigation of a spectrum of phenotypes in a hypothesis-free manner. Familial
relationships reported in EHRs have also been used for the estimation of disease heritability shown to
be consistent with the literature [285].
Multiple tools are being used by the Clinical Genetics community to address the issue of reverse
phenotyping when interpreting NGS data. This includes DECIPHER [286], a publicly-available
database that houses a collection of case-level evidence for 36,801 individuals with genetic diseases, for
comparison of phenotypic and genotypic data. Projects affiliated to DECIPHER can deposit and share
patients, variants and phenotypes to invite collaboration and increase diagnostic yield. Another example
(also accessible via DECIPHER) is that of Matchmaker Exchange [287] or Genematcher [288], for mining
other databases based on matching genotype and phenotype data. VarSome is a data aggregator that
encompasses platforms and bioinformatic tools with the aim of consolidating information required
for variant analysis. VarSome draws information from 30 databases [289] and is also embedded
into another web-based tool, VariantValidator, which enables validation, mapping and formatting of
sequence variants using HGVS nomenclature [290].
Knowledge of age-dependent and/or reduced penetrance is vital in reverse-phenotyping as new
clinical features may emerge in an individual over time. This is applicable to relatives of PAH patients
found to carry presumed pathogenic variants in known disease-associated genes. A detailed evaluation
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of multiple family members alongside longitudinal follow-up of these individuals is vital to study the
disease trajectory which has often higher definition than snapshot phenotyping at diagnosis.
Apart from mining existing databases and health records, recall by genotype (RbG) studies
will be a relevant and valuable source of information regarding the biological mechanics of
genotype–phenotype associations. By making use of the random allocation of alleles at conception
(mendelian randomization—MR) these studies enhance the ability to draw causal inferences in
population-based studies and minimise the problems related to confounders; additionally, the focus on
phenotypic assessment of a specific carrier subgroup can enhance the understanding of pathobiology
in a cost-effective manner. RbG studies can focus on a single variant or multiple variants. The former
considers rare and large effect loci to understand the biological pathways of interest, and as a result,
the groups are relatively small so the phenotype can be studied in detail, in the latter, genetic variation
is used as a proxy of relevant exposure (proviso there is a credible association between genetic markers
and exposure). To increase power for studies in which a single variant has a small effect size deployment
of aggregate genetic risk scores can be beneficial [291].
6.4. Studies
The reversal of the usual hypothesis-driven paradigm for the refined diagnosis was first used by
Grunewald and Eklund [278] who by deep clinical phenotyping of patients with Lofgren’s syndrome,
showed that erythema nodosum predominantly occurs in women and bilateral periarticular arthritis
in men, and that the acute sarcoidosis subgroup can be further characterized according to the presence
of HLA-DRB1*0301/DQB1*0201. The reverse phenotyping method has been subsequently adopted in
other disease domains (Table 4) and has led to new disease discovery, such as the Koolen–DeVries
syndrome, due to a 17q21.31 microdeletion involving the KANSL1 gene [292], and the Potocki–Lupski
Syndrome, due to a 17p11.2 microduplication [293,294]. Recently, a retrospective study of 111 patients
with nephrotic syndrome, who underwent WES, showed that reverse phenotyping increased the
diagnostic accuracy in patients referred with the diagnosis of steroid-resistant nephrotic syndrome [279].
The reverse phenotyping of BMPR2 mutation carriers has been studied in PH patients. A large
individual participant data meta-analysis found that patients with BMPR2 mutations have earlier
disease onset, worse haemodynamics, are less likely to respond to nitric oxide challenge and have lower
survival when compared to those without BMPR2 mutations [180]. The histological analysis of lungs
explanted from those patients also revealed a higher degree of bronchial artery hypertrophy/dilatation,
which correlated with the frequency of haemoptysis at presentation [295]. Patients with missense
mutations in BMPR2 that escape nonsense-mediated decay have more severe disease than those with
truncating mutations, suggestive of a dominant-negative impact of mutated protein on downstream
signalling [296]. However, missense variants in the cytoplasmic tail appear to confer less severe
phenotype than other BMPR2 variants with a later age of onset, milder haemodynamics, and more
vasoreactivity [297].
Other good candidates for reverse phenotyping are patients with a mutation in transcription
factors, i.e., TBX4, which by virtue of gene function would be associated with a more complex and
heterogeneous phenotype. Patients with mutations in TBX4 present with severe PAH associated
with bronchial and parenchymal changes, low DLCO, with or without skeletal abnormalities [142],
and bimodal age of onset [25]. Interestingly, the penetrance of TBX4 mutations for skeletal abnormalities
is much higher than for PAH [108]. Descriptions of paediatric subjects with mutations in TBX4, and likely
loci nearby including TBX2, characterised by skeletal dysplasias, developmental delay and hearing
loss have been reported in CHD and PH patients [298,299]. Interestingly, the US PAH Biobank study
confirmed a causative role of TBX4 not only across various age groups (12/266; 4.6%—paediatric-onset;
11/2345; 0.47%—adult-onset) but also across different PH phenotypes: 2 (one adult; one paediatric)/23;
8.7% PAH-CTD, 3 (two paediatric and one adult-onset)/23; 13% PAH-CHD [25]. Not all patients
harbouring deleterious variants in TBX4 fit neatly into Group 1 PH, some individuals with heterozygous
mutations in TBX4 or large deletions encompassing TBX4 were characterised by death in infancy
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secondary to acinar dysplasia [300], congenital alveolar dysplasia and pulmonary hypoplasia [301].
The studies dissecting phenotype by mutation type or looking for subtle features (i.e., SPS) among
patients harbouring deleterious variants in TBX4 who were initially diagnosed with PAH are lacking.
Reverse phenotyping of patients with PTVs in KDR revealed mild interstitial lung disease
in all index cases and one affected relative [30], which was further confirmed in an independent
case report [117].
Table 4. Examples of successful studies that used reverse phenotyping. Abbreviations: BMPR2—Bone
morphogenic protein receptor type 2; PAH—pulmonary arterial hypertension; WES—whole-exome
sequencing, * denotes allele number.
Gene Condition Study Design Data Sources Results References
HLA-DRB1*
0301/DQB1*0201 Sarcoidosis




Patients with acute onset
sarcoidosis carrying
HLA-DRB1*0301/DQB1*0201
genotype have good prognosis,
manifestations of Lofgren’s
syndrome differ between man and
woman.
[278,302]
BMPR2 PAH Retrospective analysis of169 PAH patients
WES & Health
records
Patients with missense mutations
that escape nonsense-mediated
decay have more severe disease
than those with truncating
mutations.
[296]
BMPR2 PAH Retrospective analysis of171 patients
Missense variants in the
cytoplasmic tail appear to confer
less severe phenotype than other
BMPR2 variants with a later age










BMPR2 mutations have earlier
disease onset, worse
haemodynamics, are less likely to
respond to NO challenge and
have lower survival when

















BMPR2 mutation carriers are
more prone to haemoptysis;
haemoptysis is closely correlated
to bronchial arterial remodelling
and angiogenesis; pronounced
changes in the systemic
vasculature correlate with
increased pulmonary venous
remodelling, creating a distinctive
profile in PAH patients




of all patients diagnosed
with nephrotic syndrome





Reverse phenotyping after WES
increased the diagnostic accuracy




6.5. Limitations, Challenges and Future Directions
Reverse phenotyping has the potential to shed light on genotype–phenotype associations and
accelerate the recruitment of homogenous, well-defined groups to clinical trials, thereby increasing the
chances of effective treatment and decreasing the risk of side effects. Its success depends on the quality
of forward phenotyping, and forward and reverse genetic studies accurately reporting the phenotype
of interest (use of standardised vocabulary to describe phenotypic abnormalities (i.e., HPO terms),
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clinical measurements (i.e., Logical Observation Identifiers (LOINC) [303]) and systematic approaches
to data sharing.
In the future, national and international efforts should be directed at optimising recruitment of
large homogeneous cohorts for forward genetics studies and, simultaneously, preempting any potential
ethical issues related to subsequent recall by genotype studies. Similarly, recall by genotype studies
will face challenges related to specific study design, i.e., when recruiting newborns or children who
might not express the full phenotype by the time of diagnosis/inclusion.
7. Missing Heritability in the Postgenomic Era
As already alluded to in the introduction, missing heritability is the proportion of phenotypic
variance not explained by the additive effects of known variants. There are multiple sources of missing
heritability beyond the rare and common sequence variation described above (Figure 2). In the
following paragraphs, we will discuss studies which contribute to a better understanding of the genetic
landscape in PAH, beyond germline, rare, and common sequence variation.
7.1. Unknown Genetic Variation
Recently, large case-control studies have allowed us to discover new genes involved in the
pathogenesis of PAH; all these studies, however, assumed that PAH is a monogenic condition and
examined only protein-coding space. Although this permitted the discovery of more than 16 genes
associated with PAH (Table 3), and increased the diagnostic yield, most PAH cases remain unexplained,
suggesting additional variation in non-coding regions. It is now known that the remaining 98% of
non-coding space plays a crucial role in the regulation of gene expression and requires interpretation
using its 3D structure that allows regulatory elements to function across long distances [304]. Regulatory
elements such as enhancers, promoters and actively transcribed genes are located in open-chromatin
regions so they can be accessed by transcriptional machinery. A number of methods for the identification
of non-coding regulatory elements (NCRE) have been developed over the last 20 years [305]. A recent
study investigated variation in non-coding regions by researching differences in chromatin marks
and gene expression in PAECs from patients with I/HPAH and controls. Using ChiP-Seq profiling
of the active histone marks (H3K27ac, H3K4me1, H3K4me3) and RNA-Seq, it was shown that while
PAECs from PAH patients and healthy controls are similar in terms of gene expression, they undergo
large-scale remodelling of the active chromatin regions, which leads to differential gene expression
in response to external stimuli. Overall, this study not only validated and expanded our knowledge
regarding the genes involved in the pathogenesis of PAH, but also highlighted that steady-state
expression analyses are of limited value in systems where the mechanism involves an aberrant response
to stimuli [306].
So far, mostly germline mutations have been implicated in the pathogenesis of PAH but the
ever-increasing age of onset may suggest a role of acquired somatic mutations in disease development.
While rare somatic mutations of the BMPR2 gene within pulmonary vasculature cells could cause or
aggravate BMPR2 haploinsufficiency, previous work has failed to find this to be true among those
with a germline BMPR2 mutation [307]. Conversely, a study by Aldred et al. [308] showed a high
frequency of genetically abnormal subclones of PAEC from patients with PAH including one patient
harbouring a deleterious BMPR2 variant. Similarly, Drake et al. [309] demonstrated that a somatic
deletion on chromosome 13, encompassing SMAD9, in PAECs from a patient with PAH associated
with CHD could have contributed to the pathogenesis of PAH, and potentially also to CHD [309].
Likewise, postzygotic mutations have been implicated in the pathogenesis of HHT [310] and HHT
with concomitant PAH [311,312]. Somatic mutations in TET2 have recently been reported in PAH cases,
and the phenotype was replicated in the mouse model [55].
Impaired bioenergetics is an established feature of PAH [313,314] whether its origins can be
traced back to mitochondrial DNA (mtDNA) remains an open question, but a recent study revealed
that mitochondrial haplogroups influence the risk of PAH and that susceptibility to PAH emerged
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as a result of selective enrichment of specific haplogroups upon the migration of populations out of
Africa [315]. Studies into the role of mtDNA in PAH will require novel bioinformatics tools and variant
prioritisation approaches to account for differences between nuclear and mitochondrial genomes [316].
7.2. Epigenetic Inheritance
Epigenetics are heritable changes in gene function that occur without a change in the sequence of
DNA and include DNA methylation, histone modification and RNA interference. All three of these
modifications have been shown to be involved in the development of PAH. Epigenetic changes can
be heritable [317,318], de novo and may be modified by environmental factors such as diet, smoking,
and drugs.
7.2.1. DNA Methylation
DNA methylation is a well-described form of epigenetic modification which involves the transfer
of a methyl group to cytosine residues in dinucleotide CpG sequences of DNA resulting in gene
silencing. In PAH, the best described is hypermethylation of the gene encoding superoxide dismutase
2 (SOD2), an enzyme involved in H2O2 regulation which also acts as a tumour suppressor gene.
Hypermethylation of SOD2 leads to uncontrolled cell proliferation in multiple cancers; similarly
reduced expression of SOD2 has been shown in the rat model of PH [319] and in IPAH [320]. Further
evidence comes from a recent study which found rare germline and somatic mutations in the key
regulator of DNA demethylation, TET2, in 0.39% of PAH cases [55]. The phenotype was replicated in
the Tet-/- mouse and reversed with IL-1β blockade.
7.2.2. Histone Acetylation
Histone acetylation is the most common form of histone modification [321], with a proven impact
on PAH development. In rat and human PH histone deacetylases, HDAC1 and HDAC5 concentrations
are elevated and histone deacetylase inhibitor can reverse hyperproliferation of PASMCs and decrease
mPAP and RV hypertrophy [322].
7.2.3. RNA Interference
A large number of non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs),
miRNAs, circular RNAs (circRNAs), and piwi-interacting RNAs (piRNAs) are involved in the regulation
of a variety of cellular processes. For example, so far, almost 27,000 lncRNAs have been identified in the
human genome [323] and reported regulating gene expression via diverse mechanisms [324]. In PAH,
both miRNA and lncRNAs have been studied and reported to impact cells relevant to PAH pathogenesis,
including PASMCs, PAECs and fibroblasts. Regulatory effects of lncRNA in PAH range from enhanced
proliferation of PASMCs (H19 [325], PAXIP-AS1 [326], MALAT1 [327], Inc-Ang362 [328], Tug1 [329],
HOXA-AS3 [330], MEG3 [331], TCONS_00034812 [148], and UCA1 [332]), over suppressed proliferation
and/or migration of PASMCs (MEG3 [333,334], CASC2 [335], and LnPRT [336]) to induction of EndoMT
in PAECs (MALT1 [337] and GATA6-AS [338]). Significant causative links exist between multiple
miRNAs and BMPR2 expression and signalling [339–341], as well as hypoxia [342]. Importantly,
although attractive as a therapeutic target, miRNAs have not been shown to have the potential to
reverse the disease, which is most likely due to the high degree of redundancy and “fine-tuning” rather
than “switch on/off” mode of action of these molecules.
Although still limited, our knowledge of ncRNA in the pathobiology of cardiovascular
diseases [343,344] including PAH, is rapidly growing. The major limitation of studies so far is
that the focus has been mostly on identifying the role of preselected ncRNA with very limited effort to
investigate ncRNA in a global manner accounting for multiple interactions.
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7.3. Interactions
Although difficult to estimate, gene and environment covariation and gene-environment
interactions may play a significant role in heritability, expressivity and penetration of the disease.
The most commonly studied factors are drugs, diet, toxins, radiation and stress, and some of these
factors have been implicated in the development of PAH. Definitive associations between PAH
and drugs and toxins based on outbreaks, epidemiological case-control studies or large multicentre
series have been confirmed for aminorexigenes, methamphetamines, dasatinib and toxic rapeseed oil,
yet some others require further validation [18]. Interestingly, several studies reported that BMPR2
expression and degradation can be affected by viral proteins and cocaine [345–347]. Similarly, a number
of volatile organic compounds (VOCs) identified in exhaled breath condensate in association with PAH,
are exogenous [348] and may be considered pollutants due to exposure to cigarette smoke, air pollution
and radiation [349]. Contribution of volatile compounds was also reported in the pathogenesis
of PVOD [350].
A specific example of the environmental effects on phenotype is the foetal origins of adult diseases
(FOAD) hypothesis. This hypothesis was based on the studies which reported that intrauterine exposure
increased the risk of specific cardiovascular and metabolic diseases [351–353] as well as impacted
on lung function [354–356] in adult life. In the area of PH, prenatal exposure to antidepressants and
persistent pulmonary hypertension of the newborn (PPHN) has been a subject of multiple studies.
A meta-analysis revealed that the risk for PPHN in infants exposed to SSRIs during late pregnancy
is small, although significantly increased [357]. In systemic hypertension, the transmission of gut
microbiota from parent to offspring was shown to influence the disease risk in adulthood [358] and
similarly, bacterial translocation may contribute to PAH development [359]. Air pollution was also
shown to correlate with PAH severity and outcomes [360].
With the advent of NGS, the notion of digenic or oligogenic inheritance has gained traction. HPAH
has been historically considered a monogenic condition but incomplete penetrance may indicate that
other germline or somatic variants are required for the disease to develop. Therefore, at least in a
proportion of cases, the inheritance may be digenic or even oligogenic. In the true digenic model, both
genes are required to develop the disease. Conversely, in the composite class model, a variant in one
gene is sufficient to produce the phenotype, but an additional variant in a second gene impacts the
disease phenotype or alters the age of onset [361]. The latter model seems to be plausible in PAH,
where co-occurrence of the variants in different PAH risk genes has been reported to impact on disease
onset and penetrance [362]. Patients harbouring deleterious variants in more than one PAH risk gene
have been reported in case reports [162], small [363] and large cohorts of HPAH patients [24,26,113].
Finally, the phenomenon of synergistic heterozygosity, whereby the effect of susceptibility genes is
enhanced by modifier genes, in which common variants may influence the disease onset and severity,
has been described in PAH [210].
7.4. Population Dependent Heterogeneity
It is well recognised that although rare diseases can occur in any population, some ethnic
groups are characterised by their higher incidence, i.e., sickle cell disease is more common in African,
African-Americans and Mediterranean populations and similarly, Tay-Sachs disease occurs mostly in
people of Ashkenazi Jewish or French Canadian ancestry. National and international PAH registries
have shown differences in demographic characteristics between European and East Asian patients.
East Asian IPAH cohorts resemble those of European cohorts from 40 years ago; additionally, they show
more pronounced female predominance, a younger age of onset and lower comorbidity burden, and
importantly, they demonstrate that significantly more cases can be explained by variation in known
PAH risk genes (24% [24,25] vs. 39% [26]).
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8. Summary
In this review, we have summarised how four theoretical and methodological approaches
impact genetic discoveries in rare diseases, with a particular focus on PAH. These steps include:
(1) forward phenotyping, which refers to clustering patients into homogenous groups likely to share
genetic architecture, (2) forward genetics, which aims to identify the candidate genes responsible for
the phenotype, (3) reverse genetics, which consists of experimental in vivo and in vitro targeted
modifications to candidate genes in order to analyse their phenotypic impact, and (4) reverse
phenotyping, which uses genetic marker data to refine phenotype definitions. Whilst these approaches
have been employed in PAH research, it is important to mention that at present, the majority of patients
diagnosed with PAH do not have a genetic diagnosis, a finding that indicates “missing heritability”.
To date, some progress has been made in addressing this issue; however, there is still a way to go and
only through the use of large-scale international cohorts will studies have the power to detect novel
genetic risk loci underlying PAH pathobiology and to elucidate this missing heritability.
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